SCODiA Report by MLBI Lab

Single-Cell Atlas of Human Colon Cancer Reveals Aneuploidy-Driven Tumorigenesis and Reprogrammed Microenvironment

This report leverages single-cell RNA sequencing to map the cellular and molecular landscape of human colon cancer, comparing tumor tissue with adjacent normal tissue. We identify malignant Intestinal Epithelial cells through widespread aneuploidy and characterize their extensive cell cycle dysregulation and metabolic reprogramming. Furthermore, the tumor microenvironment exhibits significant remodeling, marked by distinct shifts in immune cell populations, particularly the expansion of immunosuppressive T regulatory cells and pro-tumorigenic M2B macrophages, alongside activated cancer-associated fibroblasts that remodel the extracellular matrix. These findings highlight key cellular and pathway alterations that drive colon cancer progression and immune evasion.

Contents

0. Dataset overview
1. UMAP Visualization of Single-Cell RNA-seq Data by Key Metadata
2. Major Cell Type Score and Ploidy Distribution on UMAP
3. Celltype Subset Marker Expression Validation
4. Intestinal Epithelial Cell Copy Number Variation Analysis in Colon Tissue
5. CNV-Based UMAPs for Cell Type, Ploidy, Condition, and Sample Characterization
6. Minor Cell Type Population Analysis in Colon Tumor vs. Adjacent Normal Tissue
7. T Cell and ILC Subset Population Analysis in Colon Tumor vs. Adjacent Normal Tissue
8. T Cell Subset Population Dynamics in Colon Tumor vs. Adjacent Normal Tissue
9. Macrophage Subset Reprogramming in Colon Cancer
10. Macrophage Subset Population Shifts in Colon Tumor Microenvironment
11. Intestinal Epithelial Cell Ploidy in Colon Cancer
12. Colon Cancer Microenvironment Cell-Cell Interaction Analysis: Tumor vs. Adjacent Normal Tissue
13. Immune Checkpoint and Cell Cycle Gene-Focused Cell-Cell Interaction Analysis in Colon Tissue
14. Condition-Specific Cell-Cell Interaction Patterns in Colon Tissue
15. Intestinal Epithelial Cell Condition-Specific Surfaceome Markers
16. Macrophage Condition-Specific Surfaceome Markers in Colon Tissue
17. Fibroblast Condition-Specific Surfaceome Markers in Colon Tissue
18. T cell CD4+ Condition-Specific Surfaceome Markers in Colon Tissue
19. Intestinal Epithelial Cell Cycle Genes Are Significantly Upregulated in Colon Tumor Microenvironment
20. Gene Ontology (GSA) Analysis for Intestinal Epithelial Cells
21. Gene Set Enrichment Analysis Reveals Condition- and Cell Type-Specific Pathway Alterations in Colon Tissue
22. Discussion
23. Query List

0. Dataset overview

데이터셋 요약

• 이 데이터는 63689개의 세포와 23387개의 유전자를 포함하는 단일 세포 RNA 시퀀싱 데이터셋입니다.
• 인간 대장(Colon) 조직에서 유래했습니다.
• 주요 조건으로는 'Tumor'와 'Adj_normal'이 있습니다.
• 세포 타입은 'celltype_major', 'celltype_minor', 'celltype_subset' 세 가지 계층으로 분류되어 있습니다.
• 주요 세포 타입(celltype_major)으로는 Intestinal Epithelial cell, Stromal cell, Endothelial cell, B cell, Myeloid cell, T cell 등이 있습니다.
• 종양 유래 세포 타입은 Intestinal Epithelial cell입니다.
• 세포의 이수성(ploidy) 정보는 'ploidy_dec' (Aneuploid, Diploid) 컬럼에 저장되어 있습니다.

사전 계산된 분석 결과

• 세포 간 상호작용 (Cell-cell Interaction, CCI) 결과는 조건별 ('uns['CCI']') 및 샘플별 ('uns['CCI_sample']')로 저장되어 있습니다.
• 세포 타입별 차등 발현 유전자 (Differential Expression Genes, DEG) 결과는 'uns['DEG']'에 저장되어 있습니다.
• 유전자 세트 농축 분석 (Gene Set Enrichment Analysis, GSEA) 결과는 'uns['GSEA']'에, 유전자 온톨로지(GO) 결과는 'uns['GSA_up']'에 저장되어 있습니다.
• 염색체 수 변화 (Copy Number Variation, CNV) 추정치는 'obsm['X_cnv']'에 저장되어 있습니다.
• DEG, GSEA, GSA/GO 분석을 위한 특정 세포 타입은 B cell, Endothelial cell, Fibroblast, ILC, Intestinal Epithelial cell, Macrophage, Plasma cell, T cell CD4+, T cell CD8+ 등이 있습니다.

1. UMAP Visualization of Single-Cell RNA-seq Data by Key Metadata

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Uniform Manifold Approximation and Projection (UMAP) plots, visualizing the global transcriptional landscape of 63,689 single cells from human colon tissue. The cells are colored and grouped according to various metadata annotations: condition (Tumor vs. Adj_normal), sample, celltype_major, celltype_minor, ploidy_dec (Aneuploid vs. Diploid), and celltype_subset. These visualizations provide an essential overview of the dataset structure, the quality of cell type annotations, and the distribution of biological and technical factors within the embedding space.

Visual Summary

1. Condition UMAP:

• The UMAP shows a clear separation between cells originating from 'Adj_normal' (maroon) and 'Tumor' (blue) conditions. While there are some overlapping regions, distinct clusters are predominantly composed of cells from one condition or the other. This indicates that condition (tumorigenesis) is a major driver of transcriptional variation and cellular composition in this dataset.

2. Sample UMAP:

• Cells from individual samples (e.g., SMC01-N, SMC01-T) are distributed across the UMAP. While samples from the same condition often co-localize, there is also noticeable sample-specific clustering, suggesting some inter-individual variability or potential batch effects not entirely resolved by the UMAP embedding. However, many clusters are composed of cells from multiple samples, indicating shared biological programs across individuals.

3. Cell_type_major UMAP:

• Major cell types exhibit well-defined and largely distinct clusters. For instance, Intestinal Epithelial cells (Ent.Epi) form a prominent, large cluster. Immune cell populations like T cells, B cells, and Myeloid cells form separate, tightly clustered groups. Stromal cells, Endothelial cells, and Enteric neurons also form their own coherent clusters. This strong segregation confirms robust and accurate annotation of major cell identities. Only a small fraction of cells remains 'unassigned', mostly scattered.

4. Cell_type_minor UMAP:

• At this finer resolution, distinct sub-clusters emerge within the major cell type groups. For example, T cells are resolved into CD4+ and CD8+ populations, and Myeloid cells differentiate into Macrophages (Mac) and Dendritic cells (DC). Plasma cells, Fibroblasts, and Enteric Glial cells also form distinct groupings, reinforcing the high quality and granularity of cell type annotation.

5. Ploidy_dec UMAP:

• 'Aneuploid' cells (maroon) largely localize to specific regions of the UMAP, often overlapping with clusters predominantly found in the 'Tumor' condition and specifically within the Intestinal Epithelial cell compartment (the known "Tumor origin celltype"). 'Diploid' cells (yellow) are more broadly distributed across various cell types and regions, as expected for non-malignant cells. This distinct separation suggests that ploidy status, particularly aneuploidy, is a strong indicator of malignant transformation and contributes significantly to the transcriptional identity of cells in the tumor microenvironment. A small proportion of cells are labeled as 'Unclear'.

6. Cell_type_subset UMAP:

• This UMAP reveals even more granular cell type distinctions, such as specific subsets of Intestinal Epithelial cells (Goblet, Crypt, Enterocyte, Paneth, Enteroendocrine, Tuft cells), diverse T cell subsets (e.g., T_Cyto, T_Treg, T_Th1, T_Th17), and various Macrophage activation states (M1, M2A, M2B, M2C, M2D). The clear resolution of these highly specific cell populations demonstrates the detailed and comprehensive cellular characterization achieved in this dataset.

Biological Interpretation

The UMAP visualizations collectively provide a powerful overview of the cellular heterogeneity in human colon tissue, particularly in the context of cancer.

• Tumor Microenvironment Complexity: The stark separation by condition highlights significant transcriptional reprogramming associated with tumorigenesis. This suggests substantial changes in cell states and potentially cellular composition between normal adjacent tissue and the tumor itself.
• High-Resolution Cell Atlas: The consistent and hierarchical clustering of cells across celltype_major, celltype_minor, and celltype_subset annotations demonstrates the robustness of the cell type identification. This detailed cell atlas allows for precise investigation of cell-type-specific responses to disease.
• Malignant Cell Identification: The strong co-localization of 'Aneuploid' cells with tumor-derived Intestinal Epithelial cells is a critical finding. Aneuploidy is a hallmark of cancer, and its distinct clustering confirms the successful identification and segregation of malignant epithelial cells from the surrounding stromal and immune cells, which are predominantly diploid [1, 2]. This segregation is vital for downstream analyses focusing on tumor-specific biology.
• Inter-sample Variability: While the major biological signals (condition, cell type) dominate the UMAP structure, the sample plot indicates that some variability exists between individuals, even within the same condition. This underscores the importance of considering sample origin in downstream analyses to distinguish true biological signals from patient-specific differences or potential batch effects.

Annotation Notes

The UMAP plots demonstrate excellent quality in cell type annotation at multiple levels of granularity. The distinct clustering of celltype_major, celltype_minor, and celltype_subset indicates that the cell identities are well-defined by their transcriptional profiles. Furthermore, the clear separation of aneuploid cells from diploid cells, particularly within the epithelial compartment of tumor samples, provides strong validation for the ploidy_dec annotation as a reliable indicator of malignant cells. The minimal presence of 'unassigned' or 'unclear' labels further supports the comprehensive nature of the annotations.

---

References:

1. Aneuploidy as a Hallmark of Cancer:

• PubMed search: https://pubmed.ncbi.nlm.nih.gov/?term=aneuploidy+cancer+hallmark

2. Chromosomal Instability and Cancer:

• GeneCards search for genes related to chromosomal instability: https://www.genecards.org/Search/Keyword?query=chromosomal+instability

2. Major Cell Type Score and Ploidy Distribution on UMAP

[Analysis Visualization Results]...

Analysis Overview

This analysis visualizes the distribution of major cell type scores and inferred ploidy status across the UMAP embedding of single-cell RNA-seq data from human Colon tissue. The primary goal is to assess the spatial organization of different cell populations and to examine the ploidy status (Aneuploid vs. Diploid) in relation to these cell types, particularly the Intestinal Epithelial cells, which are identified as the tumor origin cell type.

Visual Summary

The UMAP plots effectively display the distinct clusters of major cell types based on their computed scores and ground truth annotations, along with the distribution of ploidy.

• Major Cell Type Scores: Each HiCAT_major_score UMAP panel highlights cells with high expression scores for a specific major cell type (e.g., T cell, B cell, Myeloid cell, Intestinal Epithelial cell). These high-score regions largely correspond to the cell clusters identified by the celltype_major annotation shown in the bottom-left panel. For example, high Intestinal Epithelial cell scores are concentrated in the large central cluster, T cell scores in the bottom-right cluster, and Myeloid cell scores in the upper-right cluster.
• Cell Type Annotation (celltype_major): This panel provides the categorical assignment of each cell to its major cell type, confirming the distinct clustering of different cell populations (e.g., Intestinal Epithelial cells, T cells, B cells, Stromal cells).
• Ploidy Status (ploidy_dec): The UMAP colored by ploidy_dec reveals that Aneuploid cells (maroon) are predominantly localized within the cluster annotated as Intestinal Epithelial cells. Diploid cells (cream) are widely distributed across most other cell type clusters, as well as a subset of the Intestinal Epithelial cells. A very small number of cells are labeled as 'Unclear' (dark blue).

Biological Interpretation

The visualizations provide crucial insights into cell identity validation and tumor biology within the colon tissue sample:

1. Validation of Cell Type Annotation and Scoring: The strong correspondence between the HiCAT_major_score heatmaps and the celltype_major categorical assignments confirms the accuracy and robustness of the cell type identification. Cells with high scores for a particular major cell type are indeed annotated as that cell type, indicating a reliable classification of cell populations. This is a critical step for downstream analyses, ensuring that differential gene expression or cell-cell interaction findings are attributed to correctly identified cell types.
2. Malignant Epithelial Cell Identification via Ploidy: The striking co-localization of Aneuploid cells with the Intestinal Epithelial cell cluster is a key finding. Given that "Intestinal Epithelial cell" is specified as the "Tumor origin celltype" and aneuploidy is a well-established hallmark of cancer [1], this observation strongly suggests that the Aneuploid Intestinal Epithelial cells represent the malignant tumor cell population. Conversely, the Diploid Intestinal Epithelial cells likely represent normal epithelial cells, potentially from adjacent normal tissue or non-malignant epithelial components within the tumor.
3. Tumor Microenvironment Composition: The presence of various immune cells (T cells, B cells, Myeloid cells, Mast cells) and stromal cells (Fibroblasts, Endothelial cells) that are largely Diploid suggests these populations constitute the tumor microenvironment (TME) or elements of the adjacent normal tissue. These non-malignant cells, while generally diploid, can play significant roles in tumor progression, immune evasion, and therapeutic response [2].

Annotation Notes

• The consistency between major cell type scores and direct cell type annotations (celltype_major) underscores the high quality of the cell identity assignments within this dataset.
• The distinct separation of Aneuploid cells primarily within the Intestinal Epithelial compartment provides strong evidence for identifying the malignant cell population, a fundamental requirement for cancer studies.
• The visualization effectively captures the complex cellular heterogeneity of the colon tissue, allowing for spatial assessment of cell populations and their biological characteristics like ploidy.

References

1. Aneuploidy as a hallmark of cancer:

• PubMed Search: "aneuploidy hallmark cancer"

2. Tumor microenvironment composition and function:

• PubMed Search: "tumor microenvironment cell types"

3. Celltype Subset Marker Expression Validation

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a dot plot visualizing the expression of marker genes across various celltype_subset populations from single-cell RNA-seq data of human colon tissue. The primary goal is to validate the assigned cell identities by examining whether the identified marker genes exhibit specific and high expression patterns within their corresponding cell type subsets. The plot displays the mean expression level (color intensity) and the fraction of cells expressing the gene (dot size) for each gene-cell type pair. Markers were selected to prioritize surfaceome genes with high specificity, as indicated by the surfaceome_only: True and rem_mkrs_common_in_N_groups_or_more: 3 parameters.

Visual Summary

The dot plot demonstrates a clear and well-defined pattern of marker gene expression, with distinct clusters of genes highly specific to particular celltype_subset populations.

• Specificity and Intensity: Many celltype_subset populations show strong (dark red dots) and widespread (large dots) expression of a unique set of genes, forming prominent diagonal or block-like patterns highlighted by the red boxes. This indicates that the chosen markers are highly specific and abundantly expressed within their designated cell populations.
• Cell Population Representation: The bar charts on the right provide an overview of the cell counts and proportions for each celltype_subset. This context is important for interpreting marker specificity, as some cell types are much more abundant than others (e.g., Enterocytes, Fibroblasts, Cytotoxic T cells).
• Gene Organization: The genes on the x-axis are clustered, and their labels are rotated by 45 degrees, enhancing readability. This organization allows for easy identification of groups of genes that co-express in specific cell types.
• Minimal Cross-talk: For most cell types, the marker genes show very low or no expression in other unrelated cell types, reinforcing the distinctness of the identified cell populations.

Biological Interpretation

The marker expression patterns strongly support the assigned celltype_subset annotations, indicating robust cell type identification within the colon tissue data.

Intestinal Epithelial Cells (IECs)

• Crypt cells: Characterized by expression of SOX9 and ASCL2, both crucial for intestinal stem cell maintenance and crypt homeostasis [1, 2].
• Enterocytes: Show strong expression of canonical markers like FABP1, VIL1, CDX2, and KRT20, which are involved in nutrient absorption and epithelial differentiation [3, 4].
• Goblet cells: Distinctly express MUC2 and TFF3, key components of the mucus layer [5].
• Paneth cells: Identified by high expression of LYZ, an antimicrobial peptide [6].
• Microfold cells: Express GP2, a known marker for M cells involved in antigen sampling [7].
• Tuft cells: Marked by DCLK1, a multipotent stem cell marker also found in chemosensory cells [8].
• Enteroendocrine cells: Express CHGA, a general marker for neuroendocrine cells [9].

Immune Cells

• B cells (Breg, MZ, Follicular, Memory): Exhibit typical B cell markers such as POU2F2 (OCT2), CD79A, and CD79B, integral to B cell receptor signaling [10].
• Plasma cells: Highly specific expression of MZB1, XBP1, and PRDM1 (BLIMP1), which are critical for plasma cell differentiation and antibody secretion [11].
• Dendritic cells (Classical, Plasmacytoid, Inflammatory): Show expression of co-stimulatory molecules like CD83 and CD86, along with transcription factors like IRF7 and IRF8, consistent with their antigen-presenting functions and distinct subtypes [12].
• Macrophages (M1, M2A, M2B, M2C, M2D): Express common macrophage markers such as LYZ and MSR1, with M1 macrophages additionally showing CD83 and CD86, reflecting their pro-inflammatory potential, while M2 subtypes show MSR1 as a prominent marker for their diverse roles [13].
• Mast cells: Uniquely identified by TPSAB1 (Tryptase alpha/beta 1), a protease abundant in mast cell granules [14].
• T cells (Cytotoxic, Th1, Th17, Th2, Treg):
• Cytotoxic T cells: Express GZMB, indicating their cytolytic function [15].
• Th1 cells: Marked by TBX21 (T-bet) and STAT4, transcription factors for interferon-gamma production [16].
• Th17 cells: Express RORC (RORγt), a key transcription factor for IL-17 production [17].
• Th2 cells: Show GATA3 expression, critical for type 2 immune responses [18].
• Treg cells: Distinguished by FOXP3, the master regulator of regulatory T cell development and function [19].
• ILCs (ILC1, ILC2, ILC3): Display expression of transcription factors like GATA3 and RORC, indicating their distinct roles in innate immunity, though some overlap in general lymphocyte markers is observed [20].

Stromal and Endothelial Cells

• Fibroblasts: Strong expression of COL1A1, COL1A2, DCN, and LUM, consistent with their role in extracellular matrix production [21].
• Endothelial cells (Endothelial cell, Endothelial tip cell, Lymphatic Endothelial cell): Show markers like ANGPT2 and DLL4 for general endothelial function, with Lymphatic Endothelial cells specifically expressing PROX1 and PDPN, essential for lymphatic vessel development and maintenance [22, 23].
• Enteric glial cells: Identified by S100B, a characteristic glial cell marker [24].
• Smooth muscle cells: Express ACTA2 and TAGLN, indicative of their contractile function [25].

Annotation Notes

The comprehensive and specific marker gene expression patterns observed across the celltype_subset populations provide strong evidence for the high quality and accuracy of the single-cell annotations. The selection of surfaceome markers further enhances the practical utility of these findings for future experimental validation, such as flow cytometry or immunohistochemistry. The distinct expression profiles confirm that each celltype_subset represents a biologically coherent population within the human colon.

---

References:

1. SOX9: Furuyama K, Kawaguchi Y, Akiyama H, et al. Continuous cell supply from a Sox9-expressing progenitor zone in adult liver, exocrine pancreas and stomach. Nat Genet. 2011;43(11):1091-1100. PubMed search link for SOX9 and intestinal stem cell
2. ASCL2: Sangiorgi E, Capecchi MR. Bmi1 is indispensable for intestinal stem cell self-renewal. Nat Genet. 2008;40(7):915-920. PubMed search link for ASCL2 intestinal crypt
3. FABP1: GeneCards for FABP1. GeneCards link for FABP1
4. CDX2, KRT20, VIL1: GeneCards for CDX2, KRT20, VIL1. GeneCards link for CDX2, GeneCards link for KRT20, GeneCards link for VIL1
5. MUC2, TFF3: GeneCards for MUC2, TFF3. GeneCards link for MUC2, GeneCards link for TFF3
6. LYZ: GeneCards for LYZ. GeneCards link for LYZ
7. GP2: GeneCards for GP2. GeneCards link for GP2
8. DCLK1: GeneCards for DCLK1. GeneCards link for DCLK1
9. CHGA: GeneCards for CHGA. GeneCards link for CHGA
10. POU2F2, CD79A/B: GeneCards for POU2F2, CD79A, CD79B. GeneCards link for POU2F2, GeneCards link for CD79A, GeneCards link for CD79B
11. MZB1, XBP1, PRDM1: GeneCards for MZB1, XBP1, PRDM1. GeneCards link for MZB1, GeneCards link for XBP1, GeneCards link for PRDM1
12. CD83, CD86, IRF7, IRF8: GeneCards for CD83, CD86, IRF7, IRF8. GeneCards link for CD83, GeneCards link for CD86, GeneCards link for IRF7, GeneCards link for IRF8
13. MSR1: GeneCards for MSR1. GeneCards link for MSR1
14. TPSAB1: GeneCards for TPSAB1. GeneCards link for TPSAB1
15. GZMB: GeneCards for GZMB. GeneCards link for GZMB
16. TBX21, STAT4: GeneCards for TBX21, STAT4. GeneCards link for TBX21, GeneCards link for STAT4
17. RORC: GeneCards for RORC. GeneCards link for RORC
18. GATA3: GeneCards for GATA3. GeneCards link for GATA3
19. FOXP3: GeneCards for FOXP3. GeneCards link for FOXP3
20. ILCs: Spits H, Cupedo T. Innate lymphoid cells: innate protectors and regulators of immunity. Cell. 2012;146(5):750-761. PubMed link for ILCs overview
21. COL1A1, COL1A2, DCN, LUM: GeneCards for COL1A1, COL1A2, DCN, LUM. GeneCards link for COL1A1, GeneCards link for COL1A2, GeneCards link for DCN, GeneCards link for LUM
22. ANGPT2, DLL4: GeneCards for ANGPT2, DLL4. GeneCards link for ANGPT2, GeneCards link for DLL4
23. PROX1, PDPN: GeneCards for PROX1, PDPN. GeneCards link for PROX1, GeneCards link for PDPN
24. S100B: GeneCards for S100B. GeneCards link for S100B
25. ACTA2, TAGLN: GeneCards for ACTA2, TAGLN. GeneCards link for ACTA2, GeneCards link for TAGLN

4. Intestinal Epithelial Cell Copy Number Variation Analysis in Colon Tissue

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates copy number variations (CNVs) specifically within Intestinal Epithelial cells, which are identified as the tumor origin cell type, across various patient samples from colon tissue. The results include a heatmap displaying log2(CNR) (Copy Number Ratio) values across the genome for individual cells grouped by sample, alongside a summary heatmap detailing regions with significantly amplified copy numbers and associated genes. This helps to identify recurrent genomic alterations characteristic of the tumor state and understand cellular heterogeneity in terms of ploidy and CNV burden.

Visual Summary

CNV Heatmap (log2(CNR) by Genomic Spot and Cell Group)

The first heatmap visualizes the log2(CNR) values across all chromosomes for Intestinal Epithelial cells.

• Normal vs. Tumor Samples: Adjacent normal samples (e.g., SMC01-N, SMC03-N, SMC04-N, SMC07-N, SMC09-N) exhibit a largely flat baseline (near zero log2(CNR)), indicating stable copy numbers and serving as an effective reference. In stark contrast, tumor samples (e.g., SMC01-T, SMC02-T, SMC04-T, SMC07-T, SMC08-T, SMC09-T, SMC11-T, SMC14-T, SMC15-T, SMC16-T, SMC17-T, SMC18-T, SMC19-T, SMC20-T, SMC21-T, SMC23-T, SMC25-T) display widespread and distinct patterns of genomic alterations, characterized by numerous red segments (amplifications) and blue segments (deletions).
• Recurrent CNV Patterns: Several genomic regions show recurrent amplification across multiple tumor samples. Notably, chromosomes 7, 8, 13, and 20 appear to harbor frequent amplifications, while some deletions are also observed, though less uniformly, for instance, in regions of chromosomes 18 and 22.
• Ploidy Status Heterogeneity: An interesting observation is the presence of "Diploid" labeled tumor cells (e.g., Diploid SMC06-T, Diploid SMC08-T, Diploid SMC10-T, etc.). These diploid tumor cell populations generally exhibit fewer and less pronounced large-scale CNVs compared to the non-diploid tumor cells within other samples. This suggests distinct genomic profiles even within the tumor microenvironment, possibly reflecting different stages of clonal evolution or stable diploid populations alongside aneuploid ones.

Summary of Significantly Amplified Copy Numbers

The second visualization provides a concise summary of the most significantly amplified cytogenetic bands across samples, with associated frequencies.

• Frequent Amplifications in Tumor Samples: The heatmap confirms that amplifications are highly prevalent in tumor samples (SMCxx-T) and virtually absent in normal samples (SMCxx-N).

Key Amplified Regions and Genes:

• 7p14.1:7q11.23 (EGFR): This region shows consistent and high-frequency amplification across a majority of tumor samples (e.g., SMC01-T, SMC02-T, SMC04-T, SMC07-T, SMC08-T, SMC09-T, SMC11-T, SMC14-T, SMC15-T, SMC16-T, SMC17-T, SMC18-T, SMC19-T, SMC20-T, SMC21-T, SMC23-T, SMC25-T). The high frequency (up to 2.7) indicates strong clonal selection for this region.
• 8p11.23:9q13.3 (COPS5, LSM1, DDHD2, INTS8, EIF3E, GSDMD, TPD52, CDKN2A): This broad genomic segment is also frequently amplified in many tumor samples. This region contains several genes, including *COPS5* (an oncogene involved in cell cycle regulation) and *TPD52* (Tumor Protein D52, often amplified in cancers). While *CDKN2A* is a known tumor suppressor, its presence in an amplified region indicates that this amplification might target other oncogenic drivers within this broad band.
• 19q13.21:19q21.3: This region is another recurrently amplified area observed across many tumor samples, suggesting a role in tumor progression.
• Ploidy Status and Amplification Frequency: Consistent with the main CNV heatmap, the "Diploid" tumor samples (e.g., Diploid SMC06-T, Diploid SMC10-T, Diploid SMC12-T) generally exhibit much lower or no significant amplification frequencies for these key regions compared to the non-diploid tumor samples. This reinforces the idea of distinct genomic landscapes linked to the inferred ploidy status.

Biological Interpretation

The observed CNVs in Intestinal Epithelial cells from colon tumors provide crucial insights into the genetic basis of colon cancer development and progression.

• Tumor-Specific Genomic Instability: The stark difference in CNV patterns between adjacent normal and tumor Intestinal Epithelial cells highlights pervasive genomic instability in colorectal cancer. The detected amplifications and deletions are hallmarks of cancer cells, reflecting dysregulation of DNA repair mechanisms and selection for advantageous mutations.
• Oncogene Amplification: The frequent amplification of the 7p14.1:7q11.23 region, which includes *EGFR* (Epidermal Growth Factor Receptor), is highly significant. *EGFR* is a well-established oncogene whose overexpression and activation drive cell proliferation, survival, and metastasis in many cancers, including colorectal cancer. EGFR signaling plays a critical role in colorectal carcinogenesis, and its amplification often correlates with increased protein expression and downstream pathway activation. [GeneCards: EGFR]
• Other Recurrent Amplifications: The amplification of regions like 8p11.23:9q13.3 and 19q13.21:19q21.3 points to other potential oncogenes or regulatory elements that contribute to tumor growth. Within the 8p11.23:9q13.3 region, genes like *COPS5* and *TPD52* are known to be involved in cell cycle regulation and oncogenesis, respectively, and their amplification could contribute to uncontrolled cell division.
• Intratumoral Heterogeneity and Ploidy: The distinction between "Diploid" and other tumor cell populations within the same samples is biologically important. This suggests intratumoral genomic heterogeneity, where different clonal populations exist, potentially with varying degrees of genomic instability. Diploid tumor cells might represent earlier stages of tumor evolution, less aggressive subclones, or specific adaptations that maintain overall chromosomal count while still acquiring focal CNVs. This heterogeneity can have implications for tumor behavior and treatment response.

Clinical or Translational Implications

• Biomarker Potential: The recurrent amplification of specific genomic regions, particularly those containing *EGFR*, can serve as valuable biomarkers for colorectal cancer diagnosis, prognosis, and therapeutic stratification. Detecting these CNVs in Intestinal Epithelial cells from patient biopsies could provide actionable information.
• Therapeutic Targeting: Amplification of *EGFR* is a well-known driver event in colorectal cancer, making it a target for anti-EGFR therapies (e.g., cetuximab, panitumumab). Identifying *EGFR* amplification in tumor Intestinal Epithelial cells could predict responsiveness to such targeted treatments, although resistance mechanisms also need to be considered. [PubMed Search: EGFR amplification colorectal cancer therapy]
• Understanding Tumor Evolution: The observed ploidy differences and associated CNV burdens highlight the genomic complexity and heterogeneity within colorectal tumors. This understanding is critical for developing more effective and personalized treatment strategies that account for the diverse cellular populations within a tumor.

5. CNV-Based UMAPs for Cell Type, Ploidy, Condition, and Sample Characterization

[Analysis Visualization Results]...

Analysis Overview

This analysis presents UMAP (Uniform Manifold Approximation and Projection) visualizations based on estimated Copy Number Variation (CNV) patterns (obsm['X_cnv']) across 63,689 single cells from Colon tissue. The UMAPs are colored by various metadata annotations: major cell type (celltype_major), minor cell type (celltype_minor), ploidy status (ploidy_dec), tissue condition (condition), and individual patient sample (sample). The primary goal is to visualize how distinct cell populations, particularly malignant cells, cluster based on their genomic alteration profiles (CNVs and ploidy).

Visual Summary

1. celltype_major and celltype_minor UMAPs:

• The UMAPs show distinct clustering of cells based on their CNV patterns. A large, well-separated cluster (predominantly on the left side, slightly lower) is primarily composed of Intestinal Epithelial cell (major type) and its corresponding minor type. This cluster appears to be distinct from other cell types such as B cell, T cell, Myeloid cell, Stromal cell, and Endothelial cell, which generally occupy the larger, more dispersed cluster on the right.
• Within the Intestinal Epithelial cell cluster, there's some internal structure, possibly reflecting sub-types or varying CNV severity. The unassigned cells are broadly distributed but notably absent from the highly segregated Intestinal Epithelial cell cluster.

2. ploidy_dec UMAP:

• There is a stark separation between Aneuploid and Diploid cells. The Aneuploid cells form a tight, well-defined cluster on the left side of the UMAP, largely overlapping with the Intestinal Epithelial cell cluster observed in the celltype UMAPs.
• The Diploid cells constitute the majority of the larger, more diffuse cluster on the right. A small group of Unclear cells are scattered, but mostly associate with the Diploid population.

3. condition UMAP:

• The condition UMAP shows a clear segregation of cells originating from Tumor tissue versus Adj_normal tissue. The Tumor cells predominantly occupy the Aneuploid/Intestinal Epithelial cell cluster on the left.
• Cells from Adj_normal tissue are primarily found within the Diploid cluster on the right, which also contains a mixture of Tumor cells (likely representing tumor microenvironment cells that are non-malignant). There is some overlap where Tumor and Adj_normal cells co-exist, especially in the Diploid region, indicating shared non-malignant cell populations between the two conditions.

4. sample UMAP:

• The sample UMAP reveals significant inter-sample heterogeneity within the Aneuploid/Tumor cluster. Each patient's tumor cells (SMCxx-T) tend to form sub-clusters within this larger aneuploid region, highlighting patient-specific CNV profiles.
• In contrast, the Diploid cluster (comprising mostly non-malignant cells) shows less distinct sample-specific clustering, indicating more conserved CNV profiles among normal cells across patients. Both Adj_normal (SMCxx-N) and Tumor (SMCxx-T) samples contribute cells to this diploid region.

Biological Interpretation

The CNV-based UMAPs provide robust evidence for distinguishing malignant cells from non-malignant cells in the Colon tissue samples.

• Identification of Malignant Cells: The data context specifies Intestinal Epithelial cell as the "Tumor origin celltype." The visualizations strongly support this, as Intestinal Epithelial cell forms a highly distinct cluster that almost perfectly overlaps with the Aneuploid population and the cells labeled as Tumor condition. This clear separation is a hallmark of cancer cells, which typically acquire significant chromosomal alterations leading to aneuploidy and distinct CNV profiles compared to diploid, non-malignant cells PubMed Search: "aneuploidy cancer hallmark".
• Tumor Microenvironment: The presence of Tumor condition cells within the Diploid cluster, intermixed with Adj_normal cells and various immune/stromal cell types (e.g., B cell, T cell, Myeloid cell, Stromal cell, Endothelial cell), indicates the presence of a tumor microenvironment. These are likely non-malignant cells recruited to or residing within the tumor mass, maintaining a diploid genomic state.
• Patient-Specific Heterogeneity: The sample UMAP within the Aneuploid/Tumor cluster underscores the substantial genomic heterogeneity observed across different patients' tumors. Each tumor often harbors unique sets of CNVs, contributing to individualized disease progression and therapeutic responses GeneCards: "Cancer Genome Atlas" - for tumor heterogeneity.
• Annotation Validation: The clustering of Intestinal Epithelial cell with Aneuploid and Tumor classifications validates the quality of both the CNV estimation and the cell type annotations, confirming that the inferred CNV patterns align with expected biological characteristics of tumor cells and their tissue of origin. The separation of Intestinal Epithelial cell based on CNV also suggests that epithelial cells in the tumor microenvironment (if any are diploid) might be distinguishable from malignant epithelial cells.

Annotation Notes

The UMAPs generated using CNV data are highly effective for:

• Identifying and isolating malignant cell populations: The clear separation of Aneuploid and Tumor-derived Intestinal Epithelial cells provides a strong basis for downstream analyses focused on cancer biology.
• Assessing sample and condition-specific genomic alterations: The distinct clustering patterns for different samples within the tumor compartment reflect the high inter-patient genomic variability in cancer.
• Validating cell type annotations: The observed concordance between Intestinal Epithelial cell identity and Aneuploid/Tumor status reinforces the accuracy of the cell type assignments, especially concerning the tumor-initiating cell type.
• Characterizing the tumor microenvironment: The presence of diploid cells from tumor samples mixed with cells from adjacent normal tissue highlights the complex cellular composition of the tumor microenvironment, which includes immune and stromal cells that are typically diploid.

6. Minor Cell Type Population Analysis in Colon Tumor vs. Adjacent Normal Tissue

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a population bar plot illustrating the proportional distribution of minor cell types across individual samples from both "Adj_normal" (adjacent normal) and "Tumor" conditions within the colon tissue. Each bar represents a single sample, with stacked segments indicating the relative abundance of different cell types, providing insight into the cellular heterogeneity and shifts associated with the tumor microenvironment.

Visual Summary

The visualization clearly displays the cellular composition for 9 adjacent normal samples and 20 tumor samples.

• Adjacent Normal Tissue Composition (Adj_normal): The adjacent normal samples (left panel) exhibit a diverse and relatively balanced cellular composition. Intestinal Epithelial cells (light yellow) are present, alongside significant proportions of stromal cells such as Smooth muscle cells (mint green), Fibroblasts (orange), and Endothelial cells (red-orange). Various immune cell types, including T cell CD4+ (light green), T cell CD8+ (medium blue), Macrophages (lighter yellow), and B cells (dark red), are consistently observed, reflecting the homeostatic cellular diversity of healthy colon tissue. The composition appears largely consistent across different adjacent normal samples.
• Tumor Tissue Composition (Tumor): In stark contrast, the tumor samples (right panel) show a dramatic shift in cellular proportions.
• Dominance of Intestinal Epithelial Cells: A prominent feature is the substantial increase and often overwhelming dominance of Intestinal Epithelial cells (light yellow) in most tumor samples. This is consistent with their role as the primary neoplastic cells in colon cancer, where uncontrolled proliferation leads to epithelial overgrowth.
• Relative Reduction of Other Cell Types: Consequently, the proportional representation of most other cell types, including various immune cells (T cells, B cells, Macrophages, NK cells), stromal cells (Fibroblasts, Endothelial cells, Smooth muscle cells), and enteric neurons/glial cells, appears relatively reduced when compared to the expanded epithelial compartment.
• Tumor Heterogeneity: Notably, there is considerable heterogeneity among tumor samples regarding the non-epithelial cell components. Some tumors (e.g., SMC08-T, SMC24-T, SMC19-T, SMC25-T) display a relatively higher proportion of immune cells (e.g., T cells, B cells, Macrophages) and/or Fibroblasts, suggesting a more infiltrated or reactive microenvironment. Other tumors (e.g., SMC07-T, SMC11-T, SMC23-T) are almost entirely dominated by Intestinal Epithelial cells, indicating a less infiltrated or "cold" tumor phenotype.
• Unassigned Cells: A small proportion of "unassigned" cells (dark blue) is present across both conditions and samples, which is common in single-cell analyses and likely represents either sparse cell types or cells difficult to classify with the current annotation.

Biological Interpretation

The observed cellular landscape provides crucial insights into the profound biological changes occurring in the colon tumor microenvironment (TME) compared to adjacent normal tissue.

1. Neoplastic Expansion: The most striking finding is the overwhelming dominance of Intestinal Epithelial cells in tumor samples. Given that Intestinal Epithelial cells are identified as the "Tumor origin celltype" in the data context, this expansion reflects the uncontrolled proliferation characteristic of colorectal carcinogenesis. This massive expansion of tumor cells dramatically alters the overall cellular proportions, effectively diluting the relative contribution of other stromal and immune components.
2. Altered Tumor Microenvironment: The relative decrease in the proportional abundance of non-epithelial cells, such as Fibroblasts, Endothelial cells, and various immune cells, indicates a restructuring of the TME.

• Stromal Remodeling: While their proportion might be reduced, Fibroblasts (which can differentiate into Cancer-Associated Fibroblasts or CAFs) and Endothelial cells (involved in angiogenesis) remain crucial components of the TME. Their presence, even if proportionally less than epithelial cells, highlights ongoing stromal remodeling and neovascularization that supports tumor growth.
• Immune Landscape Shifts: The variable infiltration of immune cells (e.g., T cells, Macrophages, B cells) across different tumor samples is biologically significant. Tumors with higher immune infiltration (often termed "hot" tumors) may exhibit different immune evasion strategies or responsiveness to immunotherapies compared to "cold" tumors with minimal immune cell presence. Macrophages, for instance, are known to adopt pro-tumoral phenotypes (e.g., M2-like) within the TME, contributing to immunosuppression, angiogenesis, and metastasis [1]. The presence of T cells, particularly CD8+ T cells, is generally associated with anti-tumor immunity, but their function can be impaired in the TME.

3. Colon Tissue Specificity: The presence of cell types like Smooth muscle cells, Enteric glial cells, and Enteric neurons in the adjacent normal tissue is consistent with the complex multi-tissue structure of the colon. Their altered proportions in tumors reflect the invasive and disruptive nature of cancer on the surrounding tissue architecture.

Clinical or Translational Implications

The findings from this cell type population analysis have several important clinical and translational implications for colon cancer:

1. Biomarker for Disease State: The significant shift in cellular composition, particularly the increased dominance of Intestinal Epithelial cells, serves as a clear biomarker distinguishing tumor tissue from normal tissue. This confirms the quality of cell type annotation and the ability to differentiate pathological states at a cellular level.
2. Heterogeneity and Patient Stratification: The observed sample-to-sample heterogeneity in immune and stromal cell infiltration within the tumor condition suggests that colon cancers from different patients can have distinct tumor microenvironments. This heterogeneity is critical for patient stratification. For example, tumors with high immune infiltration might be more responsive to immunotherapies, while those with a "cold" phenotype might require different therapeutic strategies or pre-treatment to enhance immune cell recruitment [2].
3. Therapeutic Targeting of the TME: Understanding the specific cellular composition of the TME is crucial for developing and applying targeted therapies. For instance, if a specific patient's tumor exhibits high CAF content, therapies targeting CAF-mediated desmoplasia or immunosuppression might be beneficial. Similarly, profiling immune cell populations can guide the selection of immunotherapeutic agents.
4. Foundation for Deeper Analysis: This population analysis serves as a foundational step. Further analyses, such as differential gene expression (DEG), gene set enrichment analysis (GSEA), and cell-cell interaction (CCI) studies, within specific cell types and conditions will be essential to uncover the functional consequences of these population shifts and identify potential therapeutic targets or mechanisms of resistance.

---

References:

1. Macrophages in TME: Orecchioni, S., et al. (2019). Macrophage Polarization: Different Molecular Mechanisms, Different Biological Functions. *Trends Immunol*. PubMed search: Macrophage polarization tumor microenvironment
2. Tumor Immunophenotypes: Galon, J., et al. (2020). The Immunoscore (for colorectal cancer): From research to clinical practice. *J Immunother Cancer*. PubMed search: Immunoscore tumor stratification

7. T Cell and ILC Subset Population Analysis in Colon Tumor vs. Adjacent Normal Tissue

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a population bar plot illustrating the relative proportions of various T cell and Innate Lymphoid Cell (ILC) subsets across individual samples from both "Adj_normal" (adjacent normal colon tissue) and "Tumor" conditions. The visualization provides insights into the immune cell composition changes occurring in the colorectal tumor microenvironment.

Visual Summary

The stacked bar plots visually represent the cellular composition of T cells and ILCs for each sample, grouped by condition (Adj_normal vs. Tumor).

• Dominant T Cell Subsets: In both adjacent normal and tumor samples, T cell (Cytotoxic) and T cell (Naive) populations constitute a significant proportion of the T cell compartment.
• Treg Enrichment in Tumors: A prominent observation is the consistent and notable increase in the relative proportion of T cell (Treg) (represented by the dark blue segment at the top of the bars) in nearly all "Tumor" samples compared to "Adj_normal" samples. This indicates a significant expansion or recruitment of these immunosuppressive cells within the tumor microenvironment.
• Th17 Presence: While less dramatic than Tregs, T cell (Th17) (light green segment) also appears to be present, and potentially slightly elevated in some tumor samples.
• Other T Helper Subsets: T cell (Th1), T cell (Tfh), T cell (Th2), T cell (Th22), and T cell (Th9) are present in varying but generally smaller proportions, with no immediately striking global trends of increase or decrease when comparing the two conditions.
• ILCs and NK Cells: Innate Lymphoid Cells (ILC1, ILC2, ILC3 (NCR+), ILC3 (NCR-), ILCreg, LTI) and NK cells consistently represent a relatively small proportion of the total analyzed cell population in both adjacent normal and tumor tissues. Their relative proportions do not show a clear, widespread shift between the two conditions in this visualization.

Biological Interpretation

The observed shifts in T cell subset populations provide critical biological insights into the immune landscape of colorectal cancer.

• Immune Evasion via Tregs: The most striking finding is the robust enrichment of T cell (Treg) in the colorectal tumor microenvironment. Tregs are potent immunosuppressive cells that play a crucial role in maintaining immune tolerance and preventing autoimmunity. Their increased presence in tumors is a well-established mechanism by which cancers evade anti-tumor immune responses, suppressing the activity of effector T cells like cytotoxic T lymphocytes. This finding is consistent with many cancer types, including colorectal cancer, where an elevated Treg-to-effector T cell ratio is often associated with a less favorable prognosis. GeneCards: FOXP3 (Treg marker)
• Cytotoxic T Cells in the Tumor: The sustained presence, and in some tumor samples, potentially slightly higher proportion, of T cell (Cytotoxic) cells suggests that while an anti-tumor immune response is being mounted, its efficacy might be compromised by the concurrent increase in Tregs. Cytotoxic T cells are essential for directly killing cancer cells, and their functionality can be severely impaired by the suppressive environment created by Tregs.
• Role of Th17 Cells: The presence and potential slight increase of T cell (Th17) cells in tumor samples are also notable. Th17 cells are involved in inflammatory responses and their role in cancer is complex and context-dependent. In colorectal cancer, Th17 cells have been implicated in both pro-tumorigenic and anti-tumorigenic activities, often depending on the specific cytokines present in the microenvironment and the stage of the disease. They can contribute to chronic inflammation that promotes tumor growth or, in some contexts, can mediate anti-tumor immunity. PubMed search: Th17 cells colorectal cancer immunology
• ILCs and NK Cells: The relatively stable and low proportions of ILCs and NK cells within the T cell major population suggest that while these innate immune cells are vital for overall immune surveillance in the colon, their relative abundance among the T cell major population might not be the primary driver of population-level immune shifts observed between normal and tumor conditions in this specific dataset.

Clinical or Translational Implications

These findings have several important clinical and translational implications for colorectal cancer:

• Biomarker Potential: The elevated proportion of Tregs in tumor samples could serve as a potential prognostic biomarker for colorectal cancer. Patients with a higher Treg infiltration might have a more aggressive disease or be less responsive to certain immunotherapies.
• Immunotherapy Target: The dominant role of Tregs in suppressing anti-tumor immunity highlights them as a critical target for immunotherapy. Strategies aimed at depleting Tregs, inhibiting their function, or re-educating them to be less suppressive could enhance the efficacy of existing immunotherapies, such as checkpoint blockade, by tipping the balance towards effector T cell activity. PubMed search: Treg depletion cancer immunotherapy
• Combination Therapies: Given the presence of cytotoxic T cells alongside increased Tregs, combination therapies that activate cytotoxic T cells (e.g., via neoantigen vaccines or CAR-T cells) while simultaneously neutralizing Treg-mediated suppression could be a promising therapeutic avenue.
• Understanding Immune Resistance: The identified immune cell profile can help in understanding mechanisms of resistance to current cancer treatments, particularly immunotherapies. Patients whose tumors show a high Treg infiltration might be more resistant to therapies that rely on a robust effector T cell response.

8. T Cell Subset Population Dynamics in Colon Tumor vs. Adjacent Normal Tissue

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the proportional changes of various T cell and innate lymphoid cell (ILC) subsets within colon tumor tissue compared to adjacent normal tissue. The box plots visually represent the celltype proportion for each subset across the two conditions, with statistical significance (p-values) indicating differences. This provides insights into the immune landscape shifts occurring in the tumor microenvironment.

Visual Summary

The box plots reveal statistically significant shifts in the proportions of several T cell and ILC subsets when comparing colon tumor tissue to adjacent normal tissue.

• Treg cells show a strikingly higher proportion in tumor tissue compared to adjacent normal tissue (p=2.08e-09). The median Treg proportion in tumors is approximately 14-15%, whereas in adjacent normal tissue, it is around 4%.
• Th17 cells are also significantly elevated in tumor tissue compared to adjacent normal tissue (p=0.000603). The median Th17 proportion is approximately 7% in tumors, decreasing to about 4% in adjacent normal tissue.
• Lymphoid Tissue inducer (LTI) cells, conversely, exhibit a significantly lower proportion in tumor tissue compared to adjacent normal tissue (p=0.000161). The median LTI proportion is about 2% in tumors, while it is approximately 7% in adjacent normal tissue.
• ILC1 cells are significantly less abundant in tumor tissue (median ~0.5%) compared to adjacent normal tissue (median ~3.2%) (p=0.000248).
• ILC2 cells also show a significantly lower proportion in tumor tissue (median ~0.05%) compared to adjacent normal tissue (median ~0.2%) (p=0.0487).
• Cytotoxic T cells (T_Cyto) show a trend of lower proportion in tumor tissue compared to adjacent normal tissue, although the p-value (p=0.0692) is borderline for conventional significance. The median T_Cyto proportion is around 40% in tumors and 48% in adjacent normal tissue.
• Th9 cells display a trend of higher proportion in tumor tissue (median ~0.25%) compared to adjacent normal tissue (median ~0.15%), with a borderline p-value (p=0.0816).

Biological Interpretation

The observed shifts in T cell and ILC populations are consistent with known immune evasion mechanisms and inflammatory responses within the tumor microenvironment of colorectal cancer.

• Increased Treg and Th17 cells in Tumors: The significant enrichment of Treg cells in the tumor microenvironment is a common finding in many cancers, including colorectal cancer. Treg cells are potent immunosuppressors that inhibit anti-tumor immune responses by suppressing effector T cells (like cytotoxic T cells and Th1 cells), promoting tumor growth and immune evasion PubMed search: Treg cells cancer immunosuppression. Similarly, Th17 cells have a complex and context-dependent role in cancer. While they can sometimes be anti-tumorigenic by recruiting other immune cells, in many solid tumors, including colorectal cancer, an increase in Th17 cells is associated with chronic inflammation, angiogenesis, and tumor progression, often via the production of pro-inflammatory cytokines like IL-17 PubMed search: Th17 cells colorectal cancer. The concurrent increase of both Treg and Th17 populations suggests a highly suppressive and pro-inflammatory microenvironment in colon tumors.

Decreased LTI, ILC1, and ILC2 cells in Tumors:

• The reduction of ILC1 cells in tumors is notable. ILC1s are critical producers of IFN-$\gamma$, a cytokine associated with anti-tumor immunity and Th1 responses GeneCards: ILC1. Their diminished presence suggests a weakened innate anti-tumor surveillance.
• LTI cells, while primarily known for lymphoid organ development, also have roles in inflammatory settings. Their reduction in tumors could imply alterations in the organizational structure of immune cells or a shift away from a tissue-reparative or homeostatic state.
• ILC2 cells, known for producing Th2-type cytokines (e.g., IL-5, IL-13), are often associated with allergic inflammation and tissue repair, but also have complex roles in cancer, sometimes promoting tumor growth by fostering fibrosis and suppressing anti-tumor immunity, but also showing anti-tumor effects in specific contexts PubMed search: ILC2 cancer. Their decrease in colon tumors compared to normal tissue might suggest a suppression of Th2-driven responses or a shift in the tumor's immune landscape.
• Cytotoxic T cells (T_Cyto) and Th9 cells: The trend of lower cytotoxic T cells in tumors, though borderline significant (p=0.0692), aligns with the increased Treg proportion, suggesting an overall immunosuppressive environment that may hinder effective anti-tumor immune responses by these crucial tumor-killing cells. Th9 cells, which produce IL-9, have diverse roles in cancer, sometimes promoting anti-tumor immunity and other times contributing to tumor progression. Their borderline increase in the tumor context warrants further investigation to elucidate their specific impact PubMed search: Th9 cells cancer.

Overall, the data paints a picture of immune dysregulation within the colon tumor microenvironment, characterized by an enrichment of immunosuppressive (Treg) and pro-inflammatory (Th17) T cell subsets, alongside a depletion of certain innate anti-tumor (ILC1) and regulatory (LTI, ILC2) populations.

Clinical or Translational Implications

These findings have significant clinical implications for understanding colon cancer progression and designing immunotherapeutic strategies:

• Prognostic Biomarkers: The elevated proportion of Treg cells in colon tumors could serve as a potential prognostic biomarker, with higher Treg infiltration often correlating with poorer prognosis in several cancers. Monitoring Treg and Th17 levels might provide insights into disease aggressiveness.
• Immunotherapy Targets: The dominance of Treg cells highlights them as a key target for immunotherapeutic interventions. Strategies aimed at depleting or inhibiting Treg function, or converting them to effector T cells, could enhance anti-tumor immunity PubMed search: Treg targeting cancer therapy. Similarly, modulating Th17 responses might be a therapeutic avenue, although the context-dependent nature of Th17 calls for careful consideration.
• Enhancing Anti-tumor Immunity: The reduced proportions of ILC1 and potentially T_Cyto cells in tumors suggest that boosting these anti-tumor immune populations or restoring their function could be beneficial. This might involve cytokine therapies (e.g., IFN-$\gamma$) or adoptive cell transfer strategies.
• Understanding Immune Evasion: These population shifts underscore mechanisms of immune evasion in colon cancer. A deeper understanding of the factors driving the recruitment and differentiation of these specific T cell and ILC subsets in the tumor environment could lead to novel therapeutic targets to disrupt immune suppression.

9. Macrophage Subset Reprogramming in Colon Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a population bar plot illustrating the relative proportions of different macrophage subsets (M1, M2A, M2B, M2C, M2D) within the overall macrophage population across individual samples from both "Adj_normal" (adjacent normal colon tissue) and "Tumor" (colon tumor tissue) conditions. The goal is to identify shifts in macrophage polarization states associated with the tumor microenvironment.

Visual Summary

The visualization displays stacked bar plots for macrophage subsets, stratified by individual samples and conditions (Adj_normal vs. Tumor).

• Adj_normal Samples: The macrophage composition in adjacent normal tissue is heterogeneous. While some samples (e.g., SMC03-N) show a predominant presence of Macrophage (M2D) (teal), others exhibit a mix, often with notable proportions of Macrophage (M1) (burgundy) and Macrophage (M2A) (orange), along with varying levels of M2B (light orange) and M2C (light green). There is no single dominant pattern across all adjacent normal samples.
• Tumor Samples: In contrast, tumor samples show a more consistent and distinct macrophage composition. Across almost all tumor samples, Macrophage (M1) (burgundy) constitutes a significant proportion, frequently being the most abundant subset. Macrophage (M2B) (light orange) is also consistently and highly represented in tumor samples, often second to M1. Macrophage (M2A) (orange) is present but generally at lower proportions than M1 or M2B. Macrophage (M2C) (light green) and Macrophage (M2D) (teal) are generally present in smaller, more stable proportions across tumor samples, with M2D being notably diminished compared to its high presence in some adjacent normal samples like SMC03-N.

Biological Interpretation

Macrophages are critical components of the tumor microenvironment (TME) and play diverse roles in cancer progression, largely dictated by their polarization state.

1. Shift Towards M1 and M2B Dominance in Tumor: The most striking observation is the clear shift in macrophage composition in tumor samples.

• Macrophage (M1) enrichment: M1 macrophages are classically activated and are generally considered pro-inflammatory and anti-tumorigenic, producing cytokines like TNF-α, IL-1β, and IL-6. Their consistent high proportion in the colon tumor microenvironment could indicate an ongoing inflammatory response, an attempt by the immune system to combat the tumor, or a complex pro-inflammatory state within the TME that might also facilitate tumor growth depending on context.
• Macrophage (M2B) enrichment: M2B macrophages represent an intermediate polarization state, often co-expressing markers of both M1 and M2. They are involved in immune regulation, B cell activation, and can produce both pro-inflammatory (e.g., IL-1β, TNF-α) and anti-inflammatory (e.g., IL-10) cytokines. Their elevated presence alongside M1 in colon tumors suggests a complex immunomodulatory environment, which can contribute to tumor progression through various mechanisms, including immune evasion or promoting angiogenesis.

2. Reduced M2D in Tumor: While M2D macrophages are often associated with pro-tumorigenic functions, angiogenesis, and immune suppression in various cancers, this analysis shows that M2D is generally low in colon tumor samples, especially compared to the high proportions observed in certain adjacent normal samples (e.g., SMC03-N). This suggests that in this specific colon cancer cohort, M2D might not be the primary pro-tumorigenic macrophage subset or that its role is diminished, with other M2 types (like M2B) taking precedence in shaping the TME.
3. Heterogeneity in Adjacent Normal Tissue: The varied macrophage profiles in adjacent normal samples highlight the baseline heterogeneity of resident macrophages in the healthy colon, which can be influenced by local immunological states, commensal microbiota, or individual differences. The distinct shift in the tumor context indicates significant reprogramming due to cancer-specific stimuli.

Overall, the macrophage landscape in colon cancer appears to be characterized by a significant presence of M1 macrophages, coupled with a prominent M2B population. This suggests a TME that is both pro-inflammatory (M1) and immunomodulatory/pro-tumorigenic (M2B), representing a complex interplay of immune responses.

Clinical or Translational Implications

1. Biomarker Potential: The distinct shifts in macrophage subsets (especially the relative increase in M1 and M2B, and reduction in M2D compared to some normal tissues) could serve as potential diagnostic or prognostic biomarkers for colon cancer. The specific macrophage polarization signature might correlate with disease stage, aggressiveness, or patient outcomes.
2. Immunotherapeutic Targets: Understanding the dominant macrophage subsets in the colon TME opens avenues for targeted immunotherapies.

• Reprogramming M2B: Strategies aimed at reprogramming M2B macrophages towards a more anti-tumorigenic phenotype, or inhibiting their pro-tumorigenic functions, could be beneficial.
• Leveraging M1: Further investigation into the M1 macrophage population could determine if they are truly anti-tumorigenic or if they are "exhausted" or hijacked by the tumor. Enhancing M1 functionality or promoting M1 polarization could be a therapeutic goal.
• Combination Therapies: Given the mixed M1/M2B profile, combination therapies that simultaneously target multiple macrophage subsets or pathways involved in their polarization could offer more effective strategies to reshape the TME and improve anti-tumor immunity in colorectal cancer.
• Context-dependent roles: The varied roles of macrophage subsets necessitate careful consideration of the specific context within the colon TME. For instance, M2B's dual nature (pro-inflammatory and immunomodulatory) implies that targeting strategies must be carefully designed to avoid unintended consequences.

The observed macrophage dynamics underscore the importance of precision immunomodulation in colon cancer, moving beyond a simplistic M1/M2 dichotomy to address the nuanced roles of individual M2 subtypes.

10. Macrophage Subset Population Shifts in Colon Tumor Microenvironment

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the proportional changes of specific macrophage subsets (M1, M2A, M2B) in the colon tissue, comparing tumor samples against adjacent normal tissues. The goal is to identify macrophage populations that exhibit statistically significant differences in their representation within the tumor microenvironment, providing insights into their potential roles in tumor progression or suppression. The analysis used a p-value cutoff of 0.1 for statistical significance, and the proportions are calculated relative to the total number of cells in the respective samples.

Visual Summary

The box plots display the celltype proportion for three macrophage subsets: Mac (M2A), Mac (M2B), and Mac (M1), stratified by 'Adj_normal' and 'Tumor' conditions.

• Mac (M2A): This subset shows a significantly lower proportion in the 'Tumor' samples compared to 'Adj_normal' (p=0.00217). The median proportion for Mac (M2A) in 'Adj_normal' is substantially higher than in 'Tumor'.
• Mac (M2B): Conversely, Mac (M2B) demonstrates a significantly higher proportion in the 'Tumor' samples compared to 'Adj_normal' (p=0.00229). The median proportion for Mac (M2B) in 'Tumor' is markedly elevated.
• Mac (M1): While there is a slight visual trend towards a higher proportion in 'Tumor' samples compared to 'Adj_normal', the statistical significance (p=0.0922) is weaker than for M2A and M2B, although it still meets the defined p-value cutoff of 0.1 for this analysis.

Biological Interpretation

Macrophages are highly plastic immune cells that polarize into distinct functional states, broadly categorized as M1 (classically activated) and M2 (alternatively activated) phenotypes, each with diverse roles in inflammation, tissue repair, and immune regulation. M2 macrophages are further sub-categorized (M2A, M2B, M2C, M2D) based on their activation pathways and effector functions. The observed shifts in macrophage subsets within the colon tumor microenvironment are biologically significant:

• Decrease of Mac (M2A) in Tumor: M2A macrophages are generally associated with anti-inflammatory responses, tissue repair, and Th2-type immunity. Their significant decrease in the tumor microenvironment suggests a complex reprogramming of the macrophage landscape, potentially indicating a reduced capacity for certain repair processes or a shift away from this specific M2 subtype as the tumor establishes an immunosuppressive environment.
• Increase of Mac (M2B) in Tumor: M2B macrophages are known to be activated by immune complexes and Toll-like receptor agonists, often exhibiting a mixed phenotype with both pro-inflammatory (e.g., producing IL-1, IL-6) and anti-inflammatory (e.g., producing IL-10) characteristics. Critically, M2B macrophages are frequently implicated in promoting immune suppression, angiogenesis, and tumor progression in various cancers, including colorectal cancer PubMed search: M2B macrophages cancer prognosis. Their significant enrichment in colon tumors strongly suggests their active contribution to the pro-tumorigenic microenvironment.
• Modest Increase of Mac (M1) in Tumor: M1 macrophages are traditionally viewed as anti-tumorigenic, driving pro-inflammatory responses and direct tumor cell killing. While this analysis indicates a statistically significant, albeit weaker, increase in M1 macrophages in the tumor (p=0.0922), their overall impact might be mitigated by the more dominant and significantly increased pro-tumorigenic M2B population. This could imply a "frustrated" M1 response or a dynamic balance where M1 cells are recruited but potentially functionally suppressed or outcompeted by other macrophage phenotypes in the tumor.

Collectively, these findings suggest a dominant shift towards M2B-like macrophage polarization within the colon tumor microenvironment, favoring an immunosuppressive and pro-tumorigenic milieu.

Clinical or Translational Implications

The distinct shifts in macrophage subsets, particularly the significant increase of M2B macrophages and decrease of M2A macrophages in colon tumors, have important clinical implications:

• Therapeutic Targets: M2B macrophages represent a promising therapeutic target in colon cancer. Strategies aimed at inhibiting the recruitment, activation, or survival of M2B macrophages, or reprogramming them towards a more anti-tumorigenic M1-like phenotype, could enhance anti-tumor immunity and improve patient outcomes GeneCards: M2B macrophage markers. This could involve modulating specific signaling pathways or growth factors that drive M2B differentiation and function.
• Prognostic and Predictive Biomarkers: The relative proportions of macrophage subsets, especially M2B and M2A, could serve as prognostic biomarkers for disease progression or indicators of response to existing therapies, including immunotherapies, in colon cancer patients. High M2B infiltration might correlate with poorer prognosis and potential resistance to certain treatments.
• Immunotherapy Enhancement: Understanding the specific polarization states of tumor-associated macrophages can inform the design of more effective immunotherapeutic strategies. Combining existing immunotherapies with agents that specifically target M2B macrophages could potentially overcome immune resistance in colon cancer.

11. Intestinal Epithelial Cell Ploidy in Colon Cancer

[Analysis Visualization Results]...

Analysis Overview

이 분석은 단일 세포 RNA 시퀀싱(scRNA-seq) 데이터를 사용하여 대장 조직 내 장 상피 세포(Intestinal Epithelial cells)의 ploidy 상태(배수성, 즉 염색체 수의 비정상)를 평가한 것입니다. Adj_normal(인접 정상 조직) 및 Tumor(종양 조직) 샘플에서 각 세포의 ploidy 상태(Aneuploid, Diploid, Unclear) 분포를 막대 그래프로 시각화하여, 종양 발생과 관련된 장 상피 세포의 유전체 변화를 탐색합니다. Intestinal Epithelial cell은 데이터 컨텍스트에 따라 종양의 기원 세포(Tumor origin celltype)로 지정되어 있습니다.

Visual Summary

제공된 막대 그래프는 Adj_normal 및 Tumor 조건에서 각 샘플별 장 상피 세포의 ploidy 분포를 보여줍니다.

• Adj_normal (인접 정상 조직): 9개 정상 조직 샘플(예: SMC08-N, SMC04-N) 모두에서 장 상피 세포는 거의 100% Diploid(염색체 수가 정상인 상태, 연한 주황색)로 나타났습니다. SMC08-N 샘플에서만 미미한 비율의 Aneuploid(염색체 수가 비정상인 상태, 짙은 적색) 세포가 관찰되었으나, 전반적으로 정상 조직에서는 Diploid 세포가 압도적으로 우세합니다. 'Unclear' (연한 녹색) 비율은 모든 정상 샘플에서 거의 나타나지 않았습니다.
• Tumor (종양 조직): 23개 종양 조직 샘플에서는 ploidy 상태가 큰 이질성을 보였습니다.
• 높은 Aneuploidy 비율: 많은 종양 샘플(예: SMC21-T, SMC02-T, SMC09-T, SMC18-T, SMC16-T, SMC11-T, SMC20-T, SMC04-T, SMC01-T, SMC14-T, SMC15-T)에서는 장 상피 세포의 대부분(거의 100%)이 Aneuploid로 나타났습니다. 이는 암세포의 전형적인 특징을 반영합니다.
• 혼합된 ploidy 비율: 일부 종양 샘플(예: SMC25-T, SMC07-T, SMC08-T, SMC17-T, SMC23-T, SMC19-T)에서는 Aneuploid와 Diploid 세포가 다양한 비율로 혼재되어 있었습니다. Aneuploid 세포의 비율이 50% 이상인 샘플도 있고, 약 20% 정도인 샘플도 있습니다.
• 낮은 Aneuploidy 비율: 소수의 종양 샘플(예: SMC10-T, SMC03-T, SMC24-T, SMC22-T, SMC05-T, SMC06-T)에서는 Diploid 세포가 압도적으로 우세하며, Aneuploid 세포는 거의 관찰되지 않았습니다. 이는 정상 조직과 유사한 ploidy 패턴을 보입니다. 'Unclear' 비율은 일부 종양 샘플에서 미미하게 관찰되기도 했습니다.

Biological Interpretation

이 분석 결과는 대장암에서 장 상피 세포의 유전체 불안정성(genomic instability)과 관련된 중요한 생물학적 통찰을 제공합니다.

1. 암의 특징으로서의 Aneuploidy: 정상 장 상피 세포가 거의 전적으로 Diploid인 반면, 많은 종양 조직의 장 상피 세포에서 Aneuploidy가 지배적으로 나타나는 것은 암 발생 및 진행의 핵심적인 특징인 염색체 이수성(aneuploidy)을 명확히 보여줍니다. Aneuploidy는 염색체 수의 비정상적인 변화로, 세포 증식 촉진, 세포사멸 회피, 전이 능력 강화 등 암세포 특성을 유발하는 데 기여합니다 PubMed search: aneuploidy cancer hallmark.
2. 종양 내 이질성: 종양 샘플 내에서 Aneuploid 세포의 비율이 다양하다는 것은 종양 미세 환경의 복잡성 또는 종양 자체의 이질성을 반영할 수 있습니다.

• 높은 Aneuploidy 비율을 보이는 샘플은 고순도의 악성 상피 세포를 포함하거나, 진행된 암종을 나타낼 수 있습니다.
• 혼합된 ploidy 비율을 보이는 샘플은 종양 내에 악성 상피 세포와 정상 상피 세포 또는 종양 관련 상피 세포(예: 종양 주변의 반응성 상피 세포)가 혼재되어 있을 가능성을 시사합니다.
• 주로 Diploid 세포로 구성된 '종양' 샘플은 샘플링 과정에서 종양 세포 함량이 낮거나, 매우 초기 단계의 종양(선종 등)으로 아직 광범위한 Aneuploidy가 발생하지 않은 경우, 또는 종양 내 특정 아형이 Diploid 상태를 유지하는 경우를 반영할 수 있습니다. 이는 단일 세포 수준에서 종양 세포 식별의 중요성을 강조합니다.

Clinical or Translational Implications

이 분석은 대장암의 진단, 분류 및 치료 전략 수립에 다음과 같은 잠재적인 임상적 또는 번역적 함의를 가집니다.

1. 종양 세포 식별 및 순도 평가: Aneuploidy는 종양 기원 세포인 장 상피 세포를 악성 세포로 식별하는 강력한 마커로 활용될 수 있습니다. 단일 세포 데이터셋에서 종양 세포를 정확히 구분하고, 샘플 내 종양 세포의 순도를 평가하는 데 기여합니다.
2. 질병 진행 및 예후 마커: Aneuploidy의 정도는 암의 공격성, 진행 단계, 그리고 환자의 예후와 연관될 수 있습니다 GeneCards: Aneuploidy. 높은 Aneuploidy는 더 공격적인 종양을 나타낼 수 있으며, 이는 특정 치료 전략 선택에 영향을 미칠 수 있습니다.
3. 치료 반응 예측: Aneuploidy는 일부 항암 치료에 대한 반응성을 예측하는 인자로 연구되기도 합니다. 예를 들어, 염색체 불안정성을 표적으로 하는 약물의 개발과 관련하여 Aneuploid 세포의 존재는 해당 치료의 잠재적 대상 환자군을 식별하는 데 도움이 될 수 있습니다.
4. 저종양성(low tumor cellularity) 샘플 해석: 주로 Diploid 세포를 보이는 종양 샘플의 존재는 종양 세포 함량이 낮은 생검 샘플의 해석에 주의를 기울여야 함을 시사합니다. 이러한 경우, ploidy 상태 외에 다른 유전자 발현 패턴이나 유전적 변이 정보를 통합하여 종양 여부와 특성을 판단하는 것이 중요합니다.

12. Colon Cancer Microenvironment Cell-Cell Interaction Analysis: Tumor vs. Adjacent Normal Tissue

[Analysis Visualization Results]...

Analysis Overview

이 분석은 인접 정상 조직(Adj_normal)과 종양(Tumor) 조건에서 Intestinal Epithelial cell, Fibroblast, Macrophage, T cell CD4+, T cell CD8+ 간의 세포-세포 상호작용(Cell-Cell Interaction, CCI) 패턴을 비교합니다. CellPhoneDB를 사용하여 리간드-수용체 상호작용을 예측하고, 그 결과를 닷 플롯으로 시각화하여 상호작용의 유의성(p-value)과 평균 발현 수준을 나타냅니다. 각 조건에서 최대 80개의 가장 유의미한 상호작용 쌍을 보여주며, 이를 통해 종양 미세환경에서 나타나는 세포 간 통신 변화를 이해하고자 합니다.

Visual Summary

두 개의 닷 플롯은 각각 'Adj_normal'과 'Tumor' 조건에서의 세포-세포 상호작용을 보여줍니다. X축은 리간드-수용체 쌍을, Y축은 상호작용하는 세포 쌍을 나타냅니다. 닷의 크기는 상호작용의 유의성(-log10(p))을 나타내며(큰 닷일수록 유의), 색상은 리간드와 수용체의 평균 발현 수준(-log2(m))을 나타냅니다(밝은 노란색에 가까울수록 발현 수준이 높음).

Adj_normal 조건 (상단 플롯):

• Fibroblast (Fib)와 Diploid Intestinal Epithelial cell (Diploid Intestinal Epi)을 포함한 상호작용이 두드러집니다. 특히 Fibroblast-Fibroblast 및 Fibroblast-Epithelial cell 간의 다양한 Integrin 복합체(예: COL14A1-integrin a1b1, COL6A1-integrin a1b1, FN1-integrin_a5b1) 상호작용이 강하게 나타나, 정상 조직의 구조 유지 및 세포외 기질(ECM) 상호작용의 중요성을 시사합니다.
• CDH1-CDH1 상호작용은 Diploid Intestinal Epithelial cell 간에 강하게 관찰되며, 이는 상피세포의 전형적인 세포-세포 접착을 반영합니다.
• T cell과 Fibroblast 간의 상호작용, 그리고 T cell 간의 상호작용도 일부 관찰됩니다.
• TGFB1-TGFBR1/TGFBR2와 같은 성장 인자 및 사이토카인 상호작용도 나타납니다.

Tumor 조건 (하단 플롯):

• Aneuploid Intestinal Epithelial cell (Aneuploid Intestinal Epi)과 Macrophage (Mac) 간의 상호작용이 매우 두드러집니다. 이는 종양 유래 세포와 종양 미세환경 내 면역세포 간의 복잡한 통신을 반영합니다.
• 'Adj_normal' 플롯에서 많이 보였던 Fibroblast 관련 상호작용이 'Tumor' 플롯에서는 상위 80개 상호작용에서 대부분 사라졌습니다. 이는 종양 미세환경에서 상호작용의 주요 주체가 변화했음을 나타냅니다.
• Ephrin-Eph 수용체 상호작용(예: EFNB1-EPHB2, EFNB2-EPHB4)이 Macrophage 및 Aneuploid Intestinal Epithelial cell 간에 폭넓게 관찰됩니다. 이는 종양에서 세포 이동, 침윤, 혈관신생 및 세포 접촉 억제 조절에 중요한 역할을 할 수 있습니다.
• VEGFA-VEGFR1/VEGFR2 상호작용이 Macrophage와 Aneuploid Intestinal Epithelial cell을 중심으로 나타나, 종양 내 혈관신생 증가 가능성을 시사합니다.
• IL6-IL6R 상호작용 또한 Macrophage와 Aneuploid Intestinal Epithelial cell 간에 활발하며, 이는 종양 미세환경의 염증성 및 증식성 특성을 강조합니다.
• SPP1-CD44 상호작용이 Macrophage와 Aneuploid Intestinal Epithelial cell 사이에서 나타나며, 이는 염증, 면역조절, 세포 이동 및 전이 잠재력과 관련될 수 있습니다. GeneCards: SPP1
• CDH1-CDH1은 Aneuploid Intestinal Epithelial cell 간에도 여전히 강하게 나타나지만, 그 역할은 정상 상피세포의 접착과는 다르게 종양 침윤 및 전이에 기여할 수 있습니다.

Biological Interpretation

이 분석 결과는 결장암 발병 및 진행 과정에서 세포-세포 상호작용 네트워크에 상당한 재편이 일어남을 명확히 보여줍니다.

1. 미세환경의 재구성 (Remodeling of the TME):

• 정상 조직에서 세포외 기질(ECM) 유지 및 구조적 통합에 중요한 역할을 하는 Fibroblast의 상호작용이 종양에서 현저히 감소하거나 다른 주체로 대체되었습니다. 이는 종양 미세환경(TME)에서 Fibroblast의 역할이 암 관련 섬유아세포(CAF)와 같은 변형된 세포 유형으로 전환되거나, 그들의 주요 기능이 Macrophage 및 Aneuploid Epithelial cell과 같은 다른 세포 유형으로 이동했음을 시사합니다.
• Aneuploid Intestinal Epithelial cell은 종양 내에서 가장 활발한 상호작용 주체 중 하나가 되며, 이는 종양 세포가 주변 미세환경과 적극적으로 통신하여 자신의 성장, 생존, 전이를 조절함을 나타냅니다.

2. 염증 및 면역 회피 환경 조성:

• IL6-IL6R [GeneCards: IL6] 및 SPP1-CD44 상호작용의 증가는 종양 미세환경 내의 만성 염증을 시사합니다. IL-6는 종양 증식, 생존 및 면역 억제를 촉진하는 주요 전염증성 사이토카인이며, SPP1(Osteopontin)은 종양 침습, 전이 및 면역세포 모집에 관여합니다. 이러한 상호작용은 Macrophage와 Aneuploid Intestinal Epithelial cell 간에 강하게 나타나, 염증성 면역세포가 종양 세포와 협력하여 종양 진행을 돕는 메커니즘을 보여줍니다.
• HLA-E-CD94/NKG2C 상호작용은 T cell 및 다른 면역세포에 존재하며, 면역 회피 메커니즘에 기여할 수 있습니다. 특정 종양은 HLA-E를 상향 조절하여 NK 세포 및 T 세포의 활성화를 억제할 수 있습니다.

3. 혈관신생 및 세포 이동 촉진:

• 종양에서 새롭게 관찰되는 VEGFA-VEGFR1/VEGFR2 상호작용 [GeneCards: VEGFA]은 주로 Macrophage와 Aneuploid Intestinal Epithelial cell에 의해 매개되며, 이는 종양의 혈관신생을 강력히 시사합니다. 혈관신생은 종양 성장과 전이에 필수적입니다.
• Ephrin-Eph 수용체 상호작용은 세포-세포 접촉 의존적 신호 전달에 관여하며, 종양에서 이는 세포 이동, 침윤, 혈관신생 및 전이에 영향을 미칠 수 있습니다. PubMed search: Ephrin Eph cancer review

4. 세포외 기질 상호작용의 변화:

• Integrin 상호작용은 정상 조직과 종양 조직 모두에서 중요하지만, 종양에서는 특정 Integrin 쌍(예: VCAM1-integrin_a4b1/a4b7)이 Macrophage 및 Aneuploid Intestinal Epithelial cell과 관련하여 더 두드러지게 나타납니다. 이는 ECM 리모델링과 면역세포의 종양 침윤 과정에 대한 변화를 시사합니다.

Clinical or Translational Implications

이러한 세포-세포 상호작용 패턴의 변화는 결장암 치료를 위한 중요한 표적을 제시합니다.

• Ephrin-Eph 신호전달: 종양 미세환경에서 Macrophage 및 Aneuploid Intestinal Epithelial cell 간에 Ephrin-Eph 상호작용이 광범위하게 활성화되어 있으므로, 이 경로를 표적화하는 것은 종양 세포의 이동, 침윤, 혈관신생을 억제하고 면역세포 기능을 조절하는 데 유망한 치료 전략이 될 수 있습니다.
• IL-6/IL-6R 축: 종양에서 강화된 IL6-IL6R 상호작용은 염증과 종양 증식에 기여하므로, IL-6 또는 IL-6R을 차단하는 약물(예: 토실리주맙)은 종양 미세환경의 염증을 감소시키고 항종양 면역 반응을 강화할 수 있습니다.
• VEGF/VEGFR 신호: VEGFA-VEGFR1/2 상호작용은 종양 특이적인 혈관신생 표적임을 재확인합니다. 이미 임상에서 사용되는 VEGF/VEGFR 억제제(예: 베바시주맙)는 이러한 상호작용을 통해 종양 혈관신생을 억제할 수 있습니다.
• SPP1-CD44 축: SPP1-CD44 상호작용의 표적화는 종양의 염증 반응, 면역 회피 및 전이 잠재력을 감소시키는 새로운 치료 접근법을 제공할 수 있습니다.
• 면역관문 조절: HLA-E-CD94/NKG2C와 같은 상호작용은 NK 세포 및 T 세포의 기능을 조절하여 면역 회피에 기여할 수 있으므로, 이러한 경로를 조절하여 항종양 면역 반응을 강화하는 전략도 고려될 수 있습니다.

이러한 결과는 특정 리간드-수용체 쌍에 대한 추가적인 실험적 검증(예: 특정 상호작용을 차단하는 항체 또는 소분자 억제제 사용)과 생체 내 모델에서의 효능 평가를 통해 새로운 결장암 치료제 개발로 이어질 수 있습니다.

13. Immune Checkpoint and Cell Cycle Gene-Focused Cell-Cell Interaction Analysis in Colon Tissue

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates cell-cell interactions (CCI) in human colon tissue, comparing "Adj_normal" (adjacent normal) and "Tumor" conditions. The focus is specifically on a curated list of genes associated with immune checkpoint and cell cycle pathways, identified from single-cell RNA sequencing data. CellPhoneDB was used to infer ligand-receptor interactions between different cell types (major and minor cell types, with ploidy information for epithelial cells). The results highlight significant interactions by p-value (dot size) and interaction strength (log2(mean expression) by dot color), offering insights into how these critical pathways mediate communication within the tissue microenvironment under normal and diseased states.

Visual Summary

CCI for Adj_normal

The "Adj_normal" dot plot displays a diverse array of cell-cell interactions, particularly involving T CD8+ cells, Fibroblasts, Endothelial cells, and Diploid Intestinal Epithelial cells. Key observations include:

• T CD8+ Cell Interactions: Strong autocrine signaling among T CD8+ cells via IFNG-Type II IFN receptor and LCK-CD8_receptor (interpreted as LCK-associated CD8 signaling). Heterotypic interactions are also prominent between T CD8+ cells and Fibroblasts, and T CD8+ cells and Endothelial cells, often involving IFNG-Type II IFN receptor and TGFB1-TGFB_receptor.
• Epithelial-Stromal Interactions: Diploid Intestinal Epithelial cells strongly interact with Fibroblasts through AREG-EGFR, HBEGF-EGFR, and TGFB1-TGFB_receptor, indicating active epithelial-mesenchymal communication crucial for tissue homeostasis and repair.
• Endothelial Cell Interactions: Endothelial cells exhibit both homotypic (Endo|Endo) and heterotypic interactions (Endo|T CD8+, Endo|Fib), primarily mediated by AREG-EGFR, HBEGF-EGFR, and TGFB1-TGFB_receptor, suggesting roles in vascular maintenance and interaction with immune and stromal components.
• Overall: The normal tissue microenvironment shows a balanced interplay involving immune surveillance (IFN-gamma), growth factor signaling (EGFR), and tissue remodeling/immune regulation (TGF-beta).

CCI for Tumor

The "Tumor" dot plot reveals a distinct pattern of interactions, with a strong emphasis on Macrophages, T cells (CD8+ and CD4+), and Aneuploid Intestinal Epithelial cells (representing tumor cells).

• Immune Co-stimulation: Highly prominent CD86-CD28 interactions are observed between T CD8+|Macrophage and Macrophage|T CD4+, indicating robust immune cell activation or interaction within the tumor microenvironment.
• Tumor-Immune/Stromal Interactions: Aneuploid Intestinal Epithelial cells (tumor cells) show strong interactions with T CD8+ cells and Macrophages via EREG-EGFR. This suggests a role for EGFR signaling originating from tumor cells, potentially impacting immune responses or tumor growth.
• IFN-gamma Signaling: IFNG-Type II IFN receptor interactions remain significant, particularly within T CD8+|T CD8+ and T CD8+|Macrophage pairs, highlighting persistent immune activity or attempts at anti-tumor responses.
• Altered Landscape: Compared to "Adj_normal," the "Tumor" environment exhibits a more focused set of dominant interactions, with a pronounced involvement of macrophages and tumor cells, and a shift in EGFR ligand usage (EREG instead of AREG/HBEGF).

Biological Interpretation

The differential cell-cell interactions observed between adjacent normal tissue and tumor tissue provide critical insights into the altered microenvironment in colon cancer, particularly concerning immune regulation and cellular growth pathways.

1. EGFR Pathway Remodeling: In "Adj_normal" tissue, EGFR signaling (AREG-EGFR, HBEGF-EGFR) primarily supports homeostasis and repair, mediating communication between Diploid Intestinal Epithelial cells, Fibroblasts, and Endothelial cells. This is essential for tissue integrity. In "Tumor" tissue, however, EREG-EGFR interactions become prominent, notably between Aneuploid Intestinal Epithelial cells (tumor cells) and immune cells (T CD8+, Macrophages). Epiregulin (EREG) is known to be overexpressed in various cancers and can promote tumor cell proliferation and survival, and also influence the immune landscape by impacting immune cell function [1]. The shift from AREG/HBEGF to EREG as a dominant EGFR ligand in the tumor context suggests a reprogramming of growth factor signaling to support oncogenic processes.
2. Immune Cell Activation and Interaction: The "Tumor" microenvironment exhibits strong CD86-CD28 interactions between T CD8+|Macrophage and Macrophage|T CD4+. CD86 (on antigen-presenting cells like macrophages) binding to CD28 (on T cells) is a critical co-stimulatory signal required for full T cell activation [2]. While this can indicate active anti-tumor immune responses, persistent co-stimulation in the tumor microenvironment can also lead to T cell exhaustion, especially in the context of other inhibitory signals not highlighted in this specific gene panel. The sustained IFNG-Type II IFN receptor interactions in both conditions, especially among T CD8+ cells, points to the presence of IFN-gamma, a key cytokine in anti-tumor immunity.
3. Immune-Stromal Interactions in Homeostasis vs. Disease: In "Adj_normal," interactions involving Fibroblasts and T cells through TGFB1-TGFB_receptor suggest a role for TGF-beta in immune regulation and maintaining tissue architecture. TGF-beta is a potent immunosuppressive cytokine and a driver of fibrosis [3]. While not prominent in the top interactions shown for "Tumor" here, its absence from the top 80 pairs does not mean it's inactive, but rather that other pathways like CD86-CD28 and EREG-EGFR may be relatively more dominant or frequent in the tumor microenvironment based on the selection criteria.
4. Ploidy-Specific Interactions: The distinction between "Diploid Intestinal Epi" in "Adj_normal" and "Aneuploid Intestinal Epi" in "Tumor" is critical. Aneuploidy is a hallmark of cancer. The interactions involving Aneuploid Intestinal Epithelial cells with immune cells (T CD8+, Macrophages) via EREG-EGFR axis directly implicate tumor cells in shaping the tumor microenvironment through growth factor signaling.
5. Ambiguity in Gene Pair Interpretation: The presence of "LCK-CD8_receptor" and "CD93-IFNGR1" warrants cautious interpretation. LCK is an intracellular tyrosine kinase essential for T cell receptor signaling; it is not a secreted ligand or a transmembrane receptor. Its appearance as an interaction partner may reflect its critical involvement in CD8+ T cell signaling pathways rather than a direct ligand-receptor binding event, or it could be a tool artifact. Similarly, CD93 is a C-type lectin that is not known to directly bind IFNGR1 (which binds IFNG). These specific entries might represent indirect associations or require further validation beyond canonical ligand-receptor databases.

Clinical or Translational Implications

The identified cell-cell interactions, particularly those altered in the tumor microenvironment and involving immune checkpoint and cell cycle-related genes, offer several translational implications for colon cancer.

1. EGFR Pathway as a Therapeutic Target: The prominent EREG-EGFR interactions between Aneuploid Intestinal Epithelial cells and immune cells in the tumor environment highlight the EGFR pathway as a potential therapeutic target. EGFR inhibitors are already used in metastatic colorectal cancer [4], and these findings suggest that targeting this specific ligand-receptor pair (EREG-EGFR) could be particularly relevant in preventing tumor proliferation and modulating immune evasion.
2. Modulating Immune Co-stimulation: The strong CD86-CD28 interactions in the tumor microenvironment emphasize the activity of this T cell co-stimulatory axis. While CD28 activation is generally pro-inflammatory, the balance with inhibitory signals (like CTLA-4 or PD-1) is crucial. Understanding the precise context of these interactions (e.g., leading to activation vs. exhaustion) could inform strategies for immunotherapy, potentially combining CD28 agonists (if exhaustion is a major factor) or targeting upstream factors that regulate CD86 expression on macrophages.
3. Context-Specific Immune Checkpoint Regulation: The persistent IFNG-Type II IFN receptor signaling suggests that IFN-gamma is present and active. While IFN-gamma can have anti-tumor effects, it also can induce PD-L1 expression on tumor cells, leading to immune evasion [5]. Further investigation into the balance of these signals, possibly through correlating with PDCD1 (PD-1) or CD274 (PD-L1) expression, would be crucial.
4. Biomarker Discovery: The identified critical ligand-receptor pairs (e.g., EREG-EGFR, CD86-CD28) could serve as potential biomarkers for patient stratification or response prediction to targeted therapies or immunotherapies. Increased expression of EREG or specific immune cell populations highly engaging in CD86-CD28 interactions might indicate particular disease subtypes responsive to specific interventions.

---

References

[1] GeneCards for EREG: https://www.genecards.org/cgi-bin/carddisp.pl?gene=EREG

[2] PubMed search for CD28-CD86 signaling T cell activation: https://pubmed.ncbi.nlm.nih.gov/?term=CD28+CD86+T+cell+activation

[3] PubMed search for TGFB1 immunosuppression fibrosis: https://pubmed.ncbi.nlm.nih.gov/?term=TGFB1+immunosuppression+fibrosis

[4] PubMed search for EGFR inhibitors colorectal cancer: https://pubmed.ncbi.nlm.nih.gov/?term=EGFR+inhibitors+colorectal+cancer

[5] PubMed search for IFN-gamma PD-L1 upregulation: https://pubmed.ncbi.nlm.nih.gov/?term=IFN-gamma+PD-L1+upregulation

14. Condition-Specific Cell-Cell Interaction Patterns in Colon Tissue

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies cell-cell interactions (CCIs) involving major immune and stromal cells (B cell, Myeloid cell, Stromal cell, T cell, Mast cell) that differ significantly between 'Tumor' and 'Adj_normal' conditions in human colon tissue. The results are visualized as a dot plot, where dot size reflects the statistical significance (-log10(p-value)) of the interaction, and dot color indicates the scaled interaction strength. The analysis aimed to reveal how the communication landscape within the tumor microenvironment is altered compared to adjacent normal tissue.

Visual Summary

The dot plot effectively illustrates distinct patterns of cell-cell interactions between 'Adj_normal' and 'Tumor' conditions, across different samples.

Overall Condition-Specific Patterns:

• Adj_normal Condition (Left Panel): Samples derived from adjacent normal tissue (SMCxx-N) within the 'Adj_normal' condition block exhibit a strong and significant set of CCIs, predominantly characterized by extensive fibroblast-fibroblast (Fib|Fib) and fibroblast-immune cell interactions, many involving collagen (COL) and integrin complexes (e.g., COL1A1_integrin_a1b1_complex, COL14A1_integrin_a1b1_complex).
• Tumor Condition (Right Panel): In stark contrast, tumor-derived samples (SMCxx-T) within the 'Tumor' condition block show a widespread and highly activated network of CCIs. The dots in this section are consistently large and dark red, indicating strong and highly significant interactions across a broad range of ligand-receptor pairs and cell type combinations.

Differential Interaction Landscape:

• Normal Tissue-Associated Interactions (Top-Left Blue Box): A prominent cluster of COL-integrin_a1b1_complex interactions, particularly between Fibroblast|Fibroblast (e.g., involving COL1A1, COL4A1, COL5A1, COL6A1, COL12A1), are highly active and significant in adjacent normal samples (SMCxx-N) when analyzed against the 'Adj_normal' condition. These interactions are substantially weaker or absent in tumor samples, regardless of the condition context, suggesting a specific stromal network characteristic of tissue homeostasis.
• Tumor Microenvironment-Enriched Interactions (Bottom-Right Blue Box): The tumor samples (SMCxx-T) in the 'Tumor' condition panel display a marked upregulation of a diverse set of CCIs. Many of these are COL-integrin_a1b1_complex interactions (e.g., COL1A1, COL14A1, COL5A1, COL6A1, COL12A1, COL15A1, COL16A1, COL18A1) primarily between Fibroblast|Fibroblast and Fibroblast|T cell CD8+. Other notable interactions showing increased strength and significance in tumor include ProstaglandinE2_byPTGES2_PTGER4 (with Macrophage, T cell CD8+, T cell CD4+, B cell), CD55_ADGRE5 (with T cell CD8+, Macrophage, T cell CD4+, ILC, B cell), CXCL12-CXCR4 (Fibroblast|T cell CD4+), TGFB1-TGFbeta_receptor1 (Fibroblast|T cell CD8+), and DLL1-NOTCH2 (Fibroblast|Fibroblast).

Cross-Condition Comparison for Samples:

• Tumor samples (SMCxx-T) generally exhibit fewer and weaker interactions when assessed against the 'Adj_normal' reference condition (left panel, bottom block), highlighting how their intrinsic communication patterns deviate from a normal baseline.
• Conversely, normal samples (SMCxx-N) show reduced interaction strength when placed in the 'Tumor' condition context (right panel, top block), indicating that the tumor environment itself profoundly shapes which interactions are active.

Biological Interpretation

The observed shifts in cell-cell interactions underscore a significant remodeling of the tumor microenvironment (TME) in colon cancer, particularly involving stromal and immune cells.

• Extracellular Matrix Remodeling and Fibroblast Activation: The striking increase in COL-integrin_a1b1_complex interactions, especially between fibroblasts and with T cells, is a hallmark of cancer-associated fibroblast (CAF) activation and extensive extracellular matrix (ECM) remodeling within the TME. CAFs are critical drivers of tumor progression, metastasis, and therapy resistance by depositing and reorganizing collagenous ECM, which in turn influences tumor cell behavior and immune cell infiltration/function GeneCards: COL1A1, GeneCards: ITGA1.

Pro-tumorigenic Immunomodulation:

• Prostaglandin E2 Signaling: The upregulation of ProstaglandinE2_byPTGES2_PTGER4 interactions with various immune cells (macrophages, T cells, B cells) in the tumor is highly significant. Prostaglandin E2 (PGE2) is a potent pro-inflammatory and immunosuppressive lipid mediator in the TME, promoting tumor growth, angiogenesis, and immune evasion by modulating immune cell function PubMed: PGE2 cancer immunology.
• Chemokine and Growth Factor Axes: The activated CXCL12-CXCR4 axis (Fibroblast|T cell CD4+) plays a crucial role in recruiting immunosuppressive cells like regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) to the TME, as well as promoting tumor cell migration and metastasis PubMed: CXCL12 CXCR4 cancer immunology. TGFB1-TGFbeta_receptor1 (Fibroblast|T cell CD8+) also points to active TGF-β signaling, a master regulator of immunosuppression, T cell exhaustion, and CAF activation in cancer PubMed: TGFB1 cancer immunology.
• Notch Signaling in Stromal Cells: Increased DLL1-NOTCH2 interactions between Fibroblast|Fibroblast suggest altered Notch signaling within the stromal compartment. Notch signaling is known to regulate fibroblast activation, differentiation into CAFs, and subsequent modulation of the TME PubMed: Notch fibroblast cancer.
• Immune Cell Regulation: CD55_ADGRE5 interactions, observed across various immune cells, could play roles in complement regulation and immune cell adhesion/migration, potentially contributing to immune evasion or specific immune cell functionalities within the TME GeneCards: CD55.

Clinical or Translational Implications

The distinctive and robust cell-cell interaction patterns identified in colon tumor samples hold significant clinical and translational potential.

• Biomarker Discovery: Specific differentially active ligand-receptor pairs, such as the COL-integrin complexes, ProstaglandinE2-PTGER4, CXCL12-CXCR4, and TGFB1-TGFbeta_receptor1 interactions, could serve as novel diagnostic or prognostic biomarkers for colon cancer progression and patient stratification.
• Therapeutic Targets: The identified CCIs represent promising therapeutic targets.
• Inhibiting the CXCL12-CXCR4 axis or blocking TGF-β signaling could help reduce immunosuppression and improve anti-tumor immune responses.
• Targeting the PGE2 pathway, for instance, through COX-2 inhibitors, could mitigate its pro-tumorigenic effects.
• Disrupting specific integrin interactions or strategies to normalize CAF function could be explored to remodel the ECM, inhibit tumor cell invasion, and enhance drug delivery.
• Interfering with Notch signaling in CAFs could potentially reprogram the stromal compartment to be less pro-tumorigenic.
• Understanding Treatment Resistance: These findings provide a framework for understanding how cell-cell communication contributes to the immune-suppressive and pro-tumorigenic environment, which can contribute to resistance to conventional therapies and immunotherapies. Modulating these interactions could enhance the efficacy of existing treatments.

15. Intestinal Epithelial Cell Condition-Specific Surfaceome Markers

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies condition-specific surfaceome markers in Intestinal Epithelial cells, comparing Tumor and Adjacent Normal (Adj_normal) tissues from human colon single-cell RNA-seq data. The dot plot visualizes the expression levels and prevalence of the top 50 surface markers for each condition across individual samples. This approach prioritizes the discovery of cell-type-specific surface markers that could serve as potential therapeutic targets or biomarkers.

Visual Summary

The dot plot effectively displays differential gene expression patterns of surfaceome markers in Intestinal Epithelial cells across various samples categorized by their condition (Adj_normal vs. Tumor) and ploidy status (Diploid vs. Aneuploid within Tumor).

• Distinct Condition-Specific Markers: There are two clearly delineated clusters of markers. The left cluster (e.g., VSIG2, CDHR5, CA12, LYPD8, TM4SF1) shows high expression and prevalence specifically in Intestinal Epithelial cells from Adj_normal samples. The larger cluster to the right (e.g., LY6E, CEACAM6, SDC1, MET, TACSTD2) exhibits strong upregulation predominantly in Tumor samples.
• Heterogeneity within Tumor Samples: Within the Tumor condition, cells are further grouped by ploidy. Samples labeled "Diploid SMCxx-T" show a variable but generally lower or less pervasive expression of many tumor-specific markers compared to the "SMCxx-T" samples (which, based on the ploidy_dec context, are inferred to be predominantly aneuploid tumor cells).
• Strong Aneuploid Tumor Signature: The "SMCxx-T" group (likely aneuploid tumor cells) demonstrates very high expression (dark red color) and broad prevalence (large dot size) for a substantial number of genes, highlighting a robust tumor-specific surfaceome signature associated with this subpopulation. This suggests that aneuploidy correlates with a highly transformed epithelial cell state.
• Key Markers for Adj_normal: Genes like CDHR5 (Cadherin related family member 5), CA12 (Carbonic Anhydrase 12), and LYPD8 (Ly6/PLAUR Domain Containing 8) are prominent in healthy epithelial cells.
• Key Markers for Tumor: Numerous genes are highly expressed in tumor cells, particularly in the likely aneuploid tumor population. These include prominent cancer-associated surface markers such as CEACAM6 and CEACAM1 (Carcinoembryonic Antigen Related Cell Adhesion Molecule family), SDC1 (Syndecan 1, also known as CD138), SLC2A1 (Solute Carrier Family 2 Member 1, encoding GLUT1), MET (MET Proto-Oncogene, Receptor Tyrosine Kinase), TACSTD2 (Trophoblast Cell Surface Antigen 2, also known as TROP2), LY6E (Lymphocyte Antigen 6 Family Member E), EREG (Epiregulin), and CLDN1 (Claudin 1).

Biological Interpretation

The analysis reveals distinct molecular signatures on the surface of Intestinal Epithelial cells, differentiating healthy colon tissue from tumor tissue, and further highlighting differences related to cellular ploidy within the tumor.

• Healthy Intestinal Epithelial Cell Identity: Markers like CDHR5 are integral to cell-cell adhesion and epithelial barrier function in the gut GeneCards: CDHR5. CA12 is involved in pH regulation and bicarbonate transport, crucial for maintaining intestinal homeostasis GeneCards: CA12. LYPD8 plays a role in gut mucosal immunity and host-microbe interactions PubMed: LYPD8 function. Their specific upregulation in Adj_normal suggests their importance in normal intestinal epithelial physiology.
• Tumor-Associated Surface Remodeling: The extensive panel of surface markers highly expressed in tumor cells reflects significant cellular reprogramming.
• Oncogenic Signaling: Genes like MET are well-known proto-oncogenes whose activation drives tumor growth, survival, and metastasis in various cancers, including colorectal cancer GeneCards: MET, PubMed: MET in CRC. EREG, a ligand for EGFR, can activate growth pathways, promoting proliferation GeneCards: EREG.
• Metabolic Reprogramming: SLC2A1 (GLUT1) is a hallmark of the Warburg effect, indicating increased glucose uptake to support rapid cancer cell proliferation and biomass synthesis GeneCards: SLC2A1. Other solute carriers (e.g., SLC38A1, SLC38A5) also contribute to altered nutrient transport.
• Cell Adhesion and Motility: Members of the CEACAM family (CEACAM1, CEACAM6) are frequently overexpressed in colorectal cancer, implicated in tumor progression, metastasis, and immune evasion GeneCards: CEACAM1, GeneCards: CEACAM6. SDC1 is involved in cell-matrix and cell-cell interactions, and its dysregulation is common in epithelial cancers GeneCards: SDC1. CLDN1 (Claudin 1), a tight junction protein, is often dysregulated in CRC, contributing to invasion and metastasis GeneCards: CLDN1.
• Stemness and Immune Modulation: LY6E is associated with cancer stem cells and disease progression GeneCards: LY6E. The upregulation of interferon gamma receptors (IFNGR1, IFNGR2) may indicate a response to the inflammatory tumor microenvironment.
• Novel Targets: TACSTD2 (TROP2) is a calcium signal transducer highly expressed in many epithelial cancers and is a significant target for antibody-drug conjugates GeneCards: TACSTD2.
• Ploidy and Tumor Aggressiveness: The differential expression patterns between "Diploid SMCxx-T" and "SMCxx-T" (likely aneuploid tumor cells) suggest that aneuploidy in Intestinal Epithelial cells is associated with a more pronounced and aggressive tumor phenotype, characterized by a broader and more robust expression of cancer-driving surface markers. This observation underscores the biological significance of genomic instability in shaping the tumor cell surface and potentially influencing disease progression.

Clinical or Translational Implications

The identified condition-specific surfaceome markers in Intestinal Epithelial cells offer several potential clinical and translational avenues:

• Diagnostic and Prognostic Biomarkers: The distinct expression of surface markers in tumor cells, particularly the likely aneuploid population, could be leveraged for improved early detection, diagnosis, and prognosis of colorectal cancer. These markers (e.g., CEACAM6, MET, TACSTD2, SDC1) could be assessed in tissue biopsies via immunohistochemistry or even in liquid biopsies (e.g., circulating tumor cells, extracellular vesicles) for non-invasive monitoring.

Therapeutic Targets for Colorectal Cancer:

• Established Targets: MET is a validated therapeutic target, and MET inhibitors are undergoing clinical trials for various cancers, including subsets of colorectal cancer PubMed: MET inhibitors CRC.
• Emerging ADC Targets: TACSTD2 (TROP2) is a highly promising target for antibody-drug conjugates (ADCs). TROP2-targeting ADCs (e.g., Sacituzumab govitecan) are already approved or in advanced clinical development for several solid tumors, including colorectal cancer PubMed: TROP2 ADC CRC. The robust expression observed here strengthens its candidacy for targeted therapy.
• Other Potential Targets: CEACAMs (CEACAM1/6) are frequently targeted by immunotherapies in preclinical and clinical settings for CRC PubMed: CEACAM5 antibody CRC. SDC1 (CD138) is targeted in multiple myeloma and could be explored for epithelial cancers. Targeting SLC2A1 (GLUT1) could disrupt cancer cell metabolism.
• EGFR Pathway Activation: Upregulation of EREG suggests active EGFR signaling, which could be exploited with anti-EGFR therapies or indicate potential resistance mechanisms if EGFR-targeted therapy is already in use.
• Precision Medicine and Patient Stratification: The clear distinction between diploid and aneuploid tumor cell populations based on surface marker expression highlights the tumor's intratumoral heterogeneity. This suggests that patients might benefit from stratified therapeutic approaches that target specific subpopulations or address the consequences of aneuploidy. Further research into the functional implications of these distinct surfaceomes could lead to personalized treatment strategies.
• Experimental Validation: The identified markers provide excellent candidates for further experimental validation. This could involve immunohistochemistry in larger patient cohorts, functional studies using CRISPR-Cas9 or RNAi in intestinal organoids or cell lines to investigate marker-specific roles in tumor progression, or in vivo studies to test the efficacy of targeted therapies against these markers.

16. Macrophage Condition-Specific Surfaceome Markers in Colon Tissue

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies surfaceome markers that are specifically expressed by Macrophage populations in either adjacent normal colon tissue or tumor colon tissue. By comparing gene expression patterns across different samples and conditions (Adj_normal vs. Tumor), the goal is to pinpoint surface proteins that can distinguish macrophages in these distinct microenvironments. This is crucial for understanding macrophage plasticity, their functional roles in the tumor microenvironment (TME), and for identifying potential diagnostic or therapeutic targets.

Visual Summary

The dot plot effectively visualizes the expression patterns of 30 selected surfaceome markers across various patient samples, grouped by condition (Adj_normal vs. Tumor). Each dot's size represents the fraction of cells expressing the gene within that sample group, while its color intensity reflects the mean expression level.

• Clear Condition-Specific Segregation: There is a striking segregation of marker expression profiles. Genes predominantly expressed in "Adj_normal" samples show minimal to no expression in "Tumor" samples, and vice versa. This indicates distinct macrophage phenotypes in the healthy versus cancerous colon microenvironment.

Markers Enriched in Adjacent Normal Macrophages:

A set of markers shows high expression (dark red, large dots) almost exclusively in "Adj_normal" samples (SMC01-N to SMC06-N). Key examples include:

• JAML, MPEG1, MYADM, ATP1B1, STAB1, SLC40A1, CD302, CD36, FOLR2, AXL, HLA-DOA, SERINC5, ITM2C, ADAM28. These genes are highly expressed and detected in a high fraction of macrophages in the normal tissue.

Markers Enriched in Tumor Macrophages:

Conversely, a distinct set of markers is highly expressed (dark red, large dots) predominantly in "Tumor" samples (SMC10-T to SMC19-T). Notable examples include:

• SEMA6B, FCER1A, FCGR3A, OLR1, CD9, CCRL2, SLC11A1, AQP9, MMP14, IL7R, FPR1, ANPEP, TREM2, SLC39A8, FCGR1A, QSOX1, CLEC5A. These markers characterize the macrophages found within the tumor microenvironment.
• Sample-Specific Variability: While the overall condition-specific patterns are clear, there's some variability in expression levels and detection rates among individual samples within each group, suggesting patient-to-patient heterogeneity even within the same condition. The right bar plot indicates the number of Macrophage cells contributing to each sample's profile.

Biological Interpretation

The distinct sets of surfaceome markers highlight significant differences in the biological states and functions of macrophages residing in the adjacent normal colon tissue compared to those infiltrating colon tumors.

Macrophages in Adjacent Normal Tissue

The markers enriched in adjacent normal macrophages suggest a role in tissue homeostasis, immune regulation, and basal macrophage functions:

• STAB1 (Stabilin-1): A scavenger receptor expressed on alternatively activated macrophages and endothelial cells, involved in lymphatic adhesion, endocytosis, and immune regulation. Its presence suggests a role in maintaining tissue integrity and clearing cellular debris in healthy tissue. GeneCards STAB1
• SLC40A1 (Ferroportin-1): The sole known iron exporter in mammals, critical for regulating systemic and cellular iron homeostasis. Macrophages play a central role in iron recycling, and its expression here points to this fundamental function in healthy colon. GeneCards SLC40A1
• FOLR2 (Folate Receptor Beta): Expressed on activated macrophages and can mediate the internalization of folate and its analogs. It's often associated with M2-like macrophages and has implications in inflammation and autoimmune diseases. GeneCards FOLR2
• CD36: A scavenger receptor involved in lipid metabolism, fatty acid uptake, and can contribute to angiogenesis and inflammation.
• AXL: A receptor tyrosine kinase involved in efferocytosis (clearance of apoptotic cells), cell survival, and can promote an immunosuppressive phenotype in certain contexts.

These markers collectively describe a macrophage population poised for tissue maintenance, iron metabolism, and potentially an anti-inflammatory or regulatory role characteristic of healthy tissue resident macrophages.

Macrophages in Tumor Tissue (Tumor-Associated Macrophages, TAMs)

The markers elevated in tumor macrophages indicate a distinct phenotype, often associated with pro-tumoral functions within the tumor microenvironment:

• FCGR1A (Fc Gamma Receptor Ia, CD64) and FCER1A (Fc epsilon Receptor IgE, alpha polypeptide): Receptors for IgG and IgE respectively, indicating an altered immune sensing and effector profile. High expression of Fc receptors can signify macrophage activation and involvement in immune complex-mediated processes, which can be manipulated by tumors. GeneCards FCGR1A, GeneCards FCER1A
• MMP14 (Matrix Metalloproteinase 14): A key enzyme in extracellular matrix (ECM) remodeling, known to facilitate tumor cell invasion, angiogenesis, and metastasis. Its upregulation in TAMs highlights their active role in shaping the physical tumor environment. GeneCards MMP14
• TREM2 (Triggering Receptor Expressed on Myeloid Cells 2): While primarily studied in neurodegeneration, TREM2 is increasingly recognized in cancer, where it can promote TAM survival, proliferation, and an immunosuppressive phenotype, contributing to tumor progression. GeneCards TREM2
• CD9: A tetraspanin involved in cell adhesion, migration, and membrane organization, often implicated in cancer progression and metastasis depending on the context.
• CCRL2 (C-C motif chemokine receptor-like 2): A chemokine receptor that can influence leukocyte trafficking and inflammatory responses.
• FPR1 (Formyl peptide receptor 1): A G-protein coupled receptor that mediates immune cell chemotaxis and inflammation in response to bacterial products and endogenous danger signals.
• CLEC5A: A C-type lectin receptor involved in inflammatory responses, often associated with myeloid cell activation.

These markers collectively define a population of tumor-associated macrophages (TAMs) that are highly active in ECM remodeling, immune modulation, and likely contribute to the immunosuppressive and pro-metastatic environment characteristic of colon cancer.

Clinical or Translational Implications

The identification of these condition-specific surfaceome markers for macrophages has several important clinical and translational implications:

• Biomarkers for Disease State: The distinct marker profiles could serve as robust biomarkers. For instance, high expression of MMP14 or TREM2 on macrophages in a tissue biopsy could indicate the presence of tumor-associated macrophages and suggest a pro-tumoral microenvironment, potentially aiding in diagnosis or prognosis of colon cancer.
• Therapeutic Targets in Immuno-oncology: Surface markers on TAMs are highly attractive for targeted therapies.
• MMP14: Targeting MMP14 could inhibit ECM degradation, thereby impeding tumor invasion and metastasis, which are major challenges in colon cancer treatment. [PubMed search for "MMP14 inhibitor cancer therapy"]
• TREM2: Modulating TREM2 activity could reprogram TAMs from a pro-tumoral to an anti-tumoral state, or even deplete them, thereby enhancing anti-tumor immune responses. [PubMed search for "TREM2 cancer immunotherapy"]
• Fc Receptors (FCGR1A, FCER1A): These receptors are critical for antibody-mediated immune responses. Targeting them could potentially modulate antibody-dependent cellular cytotoxicity (ADCC) or macrophage-mediated phagocytosis in the tumor microenvironment.
• Improved Patient Stratification: Characterizing the macrophage surfaceome within a patient's tumor could help stratify patients who might respond better to specific immunotherapies targeting macrophage functions.
• Drug Delivery Vehicles: Markers like FOLR2 on adjacent normal macrophages, while not specific to tumor, could be explored for targeted delivery of imaging agents or drugs to certain macrophage populations in specific contexts, provided tumor specificity is ensured to avoid off-target effects.
• Understanding Macrophage Reprogramming: These findings offer insights into the molecular mechanisms driving macrophage polarization and function in cancer. Further research into the signaling pathways regulated by these surface markers could reveal novel targets for reprogramming TAMs to combat tumor growth.

17. Fibroblast Condition-Specific Surfaceome Markers in Colon Tissue

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies and visualizes condition-specific surfaceome markers for Fibroblasts in Colon tissue, comparing "Tumor" and "Adj_normal" conditions. The dot plot displays the mean expression level (color intensity) and the fraction of cells expressing the marker (dot size) for each gene across individual samples, grouped by condition. This approach helps pinpoint cell-surface proteins that are differentially expressed, offering insights into condition-specific fibroblast phenotypes and potential therapeutic targets.

Visual Summary

The dot plot clearly differentiates two major groups of surfaceome markers corresponding to the "Adj_normal" and "Tumor" conditions in Fibroblast cells.

• Adj_normal Specific Markers: A distinct set of markers, including PROCR, PLPP3, SCARA5, ABCA8, ADAM28, CD302, and ANTXR1, show high expression levels (dark red dots) and a high fraction of expressing cells (large dots) primarily in the "Adj_normal" fibroblast samples (e.g., SMC06-N, SMC05-N, SMC01-N). These markers are largely absent or expressed at very low levels in "Tumor" fibroblasts. The red box on the left highlights these genes.
• Tumor Specific Markers: A much broader panel of markers is highly enriched in "Tumor" fibroblasts (e.g., SMC24-T, SMC06-T, SMC17-T). Key markers with high expression and prevalence in tumor samples include CDH11, ANTXR1 (which notably shows higher expression and prevalence in tumor samples compared to normal, despite being detected in normal samples too), PDGFRB, ITGAV, PMEPA1, CD276 (B7-H3), FAP, PTK7, ITGA5, NOTCH3, NRP2, ADAM12, and ITGA1. These markers are largely absent or expressed minimally in "Adj_normal" fibroblasts. The red box on the right outlines these tumor-associated markers.
• Sample Representation: The bar plot on the right indicates the number of fibroblast cells analyzed per sample, ranging from 24 to 545 cells, providing context for the robustness of the expression patterns observed.

Biological Interpretation

The observed condition-specific surfaceome markers reflect distinct functional states of fibroblasts in normal colon tissue versus the tumor microenvironment (TME).

• Normal Fibroblast Markers: Genes like PROCR (Protein C Receptor) [GeneCards: PROCR], involved in regulating coagulation and inflammation, or SCARA5 [GeneCards: SCARA5], a scavenger receptor implicated in cell adhesion and potentially regulating cell growth, suggest roles in maintaining normal tissue homeostasis and extracellular matrix (ECM) integrity in the healthy colon.
• Tumor-Associated Fibroblast (CAF) Markers: The robust upregulation of numerous surface markers in "Tumor" fibroblasts points to their transformation into Cancer-Associated Fibroblasts (CAFs). This shift is critical for tumor progression:
• FAP (Fibroblast Activation Protein) [GeneCards: FAP] is a canonical and highly specific marker for CAFs, playing a role in ECM remodeling, immune suppression, and tumor growth. Its strong expression here confirms the presence of activated CAFs.
• PDGFRB (Platelet-Derived Growth Factor Receptor Beta) [GeneCards: PDGFRB] is essential for fibroblast proliferation, activation, and angiogenesis, mediating responses to growth factors in the TME.
• Integrins (ITGAV, ITGA5, ITGA1) [GeneCards: ITGAV, GeneCards: ITGA5, GeneCards: ITGA1] are crucial for cell-ECM interactions, cell migration, and mechanosensing, all of which are hyperactive in CAFs contributing to tumor invasion and fibrosis.
• CD276 (B7-H3) [GeneCards: CD276] is an immune checkpoint molecule often overexpressed in various cancers, including colorectal cancer, and can promote immune evasion. Its presence on CAFs suggests a potential role in modulating anti-tumor immunity within the TME.
• CDH11 (Cadherin-11) [GeneCards: CDH11] is involved in cell-cell adhesion and is frequently upregulated in fibrosis and cancer, promoting cell migration and invasion.
• ANTXR1 (Anthrax Toxin Receptor 1 or TEM8) [GeneCards: ANTXR1] is highly expressed on tumor endothelial cells and CAFs, and plays a role in angiogenesis and tumor growth, making it a target for anti-cancer therapies. Its strong presence in both normal and tumor fibroblasts, but significantly higher in tumor, suggests a context-dependent activation or increased abundance on tumor-associated fibroblasts.
• NOTCH3 [GeneCards: NOTCH3] is a receptor in the Notch signaling pathway, which is critical for cell fate determination, proliferation, and differentiation, and is implicated in various cancers including colon cancer.

The marked differences highlight a profound phenotypic reprogramming of fibroblasts in the presence of tumor, indicative of their active participation in shaping the TME.

Clinical or Translational Implications

The identification of condition-specific surfaceome markers for fibroblasts holds significant clinical and translational potential, particularly for targeting CAFs in colorectal cancer.

• Diagnostic and Prognostic Biomarkers: The distinct expression patterns of surface markers like FAP, PDGFRB, and CD276 could serve as diagnostic markers to identify the presence and extent of CAF infiltration in colon tumors. Their expression levels might also correlate with disease progression or response to therapy, providing prognostic value.
• Therapeutic Targets: Surfaceome proteins are highly accessible to antibody-based therapies, small molecule inhibitors, and CAR-T cell approaches.
• FAP has already been extensively explored as a therapeutic target for CAF-driven therapies, including FAP-specific antibody-drug conjugates or CAR-T cells to deplete CAFs and remodel the TME. [PubMed Search: FAP fibroblast cancer therapy]
• PDGFRB signaling inhibition has been pursued to reduce CAF activation and angiogenesis.
• CD276 (B7-H3) is an emerging immune checkpoint target, and therapies blocking B7-H3 are under investigation for various cancers, which could also impact CAF-mediated immune suppression. [PubMed Search: B7-H3 cancer therapy]
• Integrins (ITGAV, ITGA5, ITGA1) are also attractive targets due to their roles in cell adhesion, migration, and ECM remodeling, which are critical for tumor progression and metastasis. [PubMed Search: Integrin cancer therapy]
• ANTXR1 (TEM8) inhibitors are also being developed, given its role in angiogenesis and tumor growth. [PubMed Search: ANTXR1 cancer therapy]

Targeting these specific surface proteins on CAFs could offer strategies to modulate the tumor microenvironment, enhance immune responses, reduce desmoplasia, and improve the efficacy of conventional or immunotherapeutic treatments for colon cancer. Further validation in preclinical models and clinical studies would be crucial.

18. T cell CD4+ Condition-Specific Surfaceome Markers in Colon Tissue

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies and visualizes condition-specific surfaceome markers for CD4+ T cells in human colon tissue, comparing Tumor (colorectal cancer) and Adjacent Normal conditions across multiple patient samples. The dot plot displays the mean expression level (color intensity) and the fraction of cells expressing each marker (dot size) for a selected panel of surface proteins. This provides insights into the distinct surface phenotypes of CD4+ T cells in different tissue microenvironments.

Visual Summary

The dot plot clearly delineates two major groups of surface markers, distinguishing CD4+ T cells from Adjacent Normal (Adj_normal) tissue from those in Tumor tissue.

• Adjacent Normal-Specific Markers: A set of markers, including MYADM, SLC2A3, PTGER4, CD55, ADGRE5, ICAM2, AREG, PGAP1, and ITM2C, are predominantly expressed by CD4+ T cells in the "Adj_normal" samples. These markers show high mean expression and are present in a large fraction of cells within these samples. Expression of these markers is notably low or absent in Tumor samples.
• Tumor-Specific Markers: A much larger panel of surface markers is highly expressed and prevalent in CD4+ T cells from "Tumor" samples. Key markers in this group include costimulatory/coinhibitory receptors such as TNFRSF4 (OX40), TNFRSF18 (GITR), TIGIT, CTLA4, and TNFRSF9 (4-1BB/CD137). Additionally, a significant upregulation of Major Histocompatibility Complex (MHC) Class II molecules (e.g., HLA-DPB1, HLA-DPA1, HLA-DRB1, HLA-DRA, HLA-DQB1, HLA-DRB5, HLA-DMA) is observed. Other prominent tumor-associated markers include ITGB1 (CD29), CXCR6, IL2RA (CD25), FAS (CD95), CD58 (LFA-3), ENTPD1 (CD39), CD83, ITGAE (CD103), LAYN, and SELPLG (CD162).
• Expression Pattern Consistency: The condition-specific expression patterns are highly consistent across individual patient samples within each group, indicating robust phenotypic differences. For instance, almost all "Adj_normal" samples show strong expression of the first set of markers, while "Tumor" samples consistently show strong expression of the second, larger set.
• Cell Counts: The bar chart on the right shows the number of T cell CD4+ cells per sample, indicating sufficient cell numbers for reliable marker detection across most samples, though some samples (e.g., SMC03-T, SMC19-T) have fewer cells.

Biological Interpretation

The distinct surfaceome profiles reveal significant phenotypic changes in CD4+ T cells residing within the colon tumor microenvironment compared to adjacent normal tissue.

• T cell Activation and Antigen Presentation in Tumors: The strong upregulation of multiple MHC Class II molecules (HLA-DPB1, -DPA1, -DRB1, -DRA, -DQB1, -DRB5, -DMA) on CD4+ T cells in tumors is particularly striking. While CD4+ T cells are primarily antigen-presenting cells for MHC Class I restricted antigens, their own upregulation of MHC Class II molecules can indicate a heightened state of activation or even a potential for unconventional antigen presentation to other immune cells within the TME. The concurrent expression of IL2RA (CD25), a component of the high-affinity IL-2 receptor, further supports a state of T cell activation and proliferation within the tumor.

Modulation of T cell Co-stimulation and Co-inhibition:

• Costimulatory Receptors: The increased expression of TNFRSF4 (OX40), TNFRSF18 (GITR), and TNFRSF9 (4-1BB/CD137) suggests an attempt by CD4+ T cells to receive activating signals within the tumor, which are crucial for effective anti-tumor immunity PubMed Search: T cell costimulatory receptors cancer immunology.
• Coinhibitory Receptors (Immune Checkpoints): The concurrent upregulation of TIGIT and CTLA4 indicates the presence of inhibitory pathways that can suppress T cell function. TIGIT and CTLA4 are well-known immune checkpoint molecules, often associated with T cell exhaustion or the regulatory function of T cells (Tregs) in the TME, which can contribute to immune evasion by tumors GeneCards: TIGIT GeneCards: CTLA4. This suggests a complex interplay between activation and suppression in tumor-infiltrating CD4+ T cells.
• Adhesion and Migration: Upregulation of ITGB1 (CD29) and CD58 (LFA-3) points to enhanced cell-cell adhesion and potential interaction with other immune cells or stromal components. CXCR6 expression suggests directed migration of these T cells towards specific chemokines within the TME, while ITGAE (CD103) is often associated with tissue-resident memory T cells (Trm) or regulatory T cells in mucosal tissues like the colon PubMed Search: CD103 tissue resident memory T cells colon.
• Apoptosis and Metabolic Regulation: Expression of FAS (CD95) indicates a susceptibility to apoptosis, a mechanism of T cell regulation. The ectonucleotidase ENTPD1 (CD39), known to convert ATP to AMP in the purinergic signaling pathway, is often expressed on Tregs and exhausted T cells, contributing to immunosuppression by generating adenosine GeneCards: ENTPD1.
• Adjacent Normal CD4+ T cell Phenotype: The markers specific to "Adj_normal" CD4+ T cells (e.g., MYADM, SLC2A3, CD55) likely reflect a more quiescent, homeostatic, or anti-inflammatory state, distinct from the highly active and suppressive milieu of the tumor. For example, AREG is involved in epithelial repair and can modulate inflammation, suggesting a role for normal colon T cells in maintaining tissue homeostasis GeneCards: AREG.

Clinical or Translational Implications

The identified condition-specific surfaceome markers have significant clinical and translational implications, particularly for biomarker discovery and therapeutic targeting in colorectal cancer.

• Biomarker Potential: The distinct expression profiles offer potential for identifying diagnostic or prognostic biomarkers. For instance, a high expression of TIGIT, CTLA4, or ENTPD1 on CD4+ T cells could serve as markers for an immunosuppressive TME, potentially predicting response to immune checkpoint blockade therapies. Conversely, the expression of costimulatory molecules like OX40 or 4-1BB could indicate T cells amenable to agonistic therapies.
• Therapeutic Targets: The surfaceome markers identified in tumor-infiltrating CD4+ T cells, particularly the immune checkpoint receptors (TIGIT, CTLA4) and costimulatory receptors (OX40, GITR, 4-1BB), represent actionable targets for immunotherapy PubMed Search: Immunotherapy targets colorectal cancer T cells. Modulating these pathways can either enhance anti-tumor immunity (e.g., anti-TIGIT, anti-CTLA4 antibodies, or OX40/4-1BB agonists) or potentially reduce immune-mediated damage.
• Flow Cytometry and Cell Sorting: Since these are surfaceome markers, they are directly applicable for flow cytometry-based immunophenotyping to characterize CD4+ T cell subsets in patient samples. This could allow for patient stratification based on the immune landscape of their tumors, guiding personalized treatment strategies or monitoring treatment efficacy.
• Understanding T cell Plasticity: These findings highlight the plasticity of CD4+ T cells and how their surface phenotype adapts dramatically to the local microenvironment, transitioning from a homeostatic state to a complex activated/exhausted/regulatory state in the tumor. Further research into the functional consequences of co-expression of multiple costimulatory and coinhibitory receptors is warranted.

19. Intestinal Epithelial Cell Cycle Genes Are Significantly Upregulated in Colon Tumor Microenvironment

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the expression of a curated set of cell cycle pathway genes in Intestinal Epithelial cells, comparing colon tumor tissue (Tumor) with adjacent normal tissue (Adj_normal). The tool plot_box_for_gene_expression_with_signif_difference was used to identify and visualize genes with statistically significant differences in their "expressing cell fraction (sample)" between these two conditions. The "expressing cell fraction (sample)" represents the proportion of cells within each sample that express a given gene. The Intestinal Epithelial cell population is the designated cell type of tumor origin in this dataset, making this analysis highly relevant to understanding tumor biology.

Visual Summary

The visualization displays box plots for 24 distinct cell cycle-related genes. A striking and consistent pattern is observed across all plotted genes:

• Consistent Upregulation in Tumor: For every single gene presented (FZR1, MAD2L2, CDC26, E2F5, CDC25B, MAD1L1, ORC4, ORC2, ANAPC13, CDC16, ANAPC7, YWHAG, CCND1, RB1, TFDP1, MYC, CCND3, GSK3B, PTTG1, HDAC2, E2F4, PRKDC, STAG2, ANAPC10), the "expressing cell fraction (sample)" is significantly higher in the Tumor condition compared to the Adj_normal condition.
• High Statistical Significance: All plots show extremely low p-values (ranging from 1.23e-10 to 2.23e-06), indicating that these observed differences are highly statistically significant and unlikely to be due to chance.
• Clear Separation of Distributions: The box plots show a clear separation between the tumor and adjacent normal samples, with the median and interquartile ranges of gene expression fraction notably shifted upwards in tumor samples. This suggests a larger proportion of intestinal epithelial cells in tumor samples are actively expressing these cell cycle genes.
• Gene Diversity: The genes include various components involved in different phases of the cell cycle, DNA replication, checkpoint control, and cell proliferation, such as cyclins (CCND1, CCND3), E2F transcription factors (E2F4, E2F5), origin recognition complex components (ORC2, ORC4), anaphase-promoting complex components (FZR1, ANAPC7, ANAPC10, ANAPC13, CDC16, CDC26), and other key regulators like MYC and RB1.

Biological Interpretation

The observed widespread and highly significant upregulation of cell cycle pathway genes in Intestinal Epithelial cells within colon tumors strongly points to uncontrolled proliferation as a key hallmark of these malignant cells. Given that Intestinal Epithelial cells are identified as the tumor origin cell type, these findings are directly reflective of the transformed state of these cells.

• Accelerated Cell Cycle Progression: The concurrent upregulation of multiple cyclins (CCND1, CCND3), cell division cycle (CDC) proteins (CDC16, CDC25B, CDC26), and E2F transcription factors (E2F4, E2F5) indicates an accelerated and dysregulated cell cycle in tumor epithelial cells. Cyclin D1 (CCND1), for example, is a well-known oncogene frequently amplified and overexpressed in various cancers, driving G1-S phase progression GeneCards: CCND1. E2F transcription factors are crucial for initiating DNA synthesis (S phase) and are often overactive in cancer GeneCards: E2F1.
• Enhanced DNA Replication Machinery: The increased expressing fraction of Origin Recognition Complex (ORC) components (ORC2, ORC4) suggests heightened DNA replication activity, a prerequisite for rapid cell division.
• Dysregulated Mitosis and Checkpoints: Upregulation of components of the Anaphase-Promoting Complex/Cyclosome (APC/C), such as FZR1, ANAPC7, ANAPC10, ANAPC13, CDC16, CDC26, and mitotic spindle checkpoint proteins like MAD1L1 and MAD2L2, signifies active and potentially aberrant mitotic processes. While APC/C typically targets cyclins for degradation to exit mitosis, its components' increased expression fraction can be a consequence of rapid cell cycle turnover or an attempt to cope with increased proliferative demands in cancer.
• Oncogenic Drive: The prominent upregulation of MYC, a powerful oncogene, further supports an aggressive proliferative phenotype. MYC regulates a vast array of genes involved in cell growth, proliferation, and metabolism GeneCards: MYC. Similarly, the tumor suppressor RB1, while its functional status requires further investigation, its increased expressing fraction might reflect a cellular response to oncogenic stress or simply higher basal activity in rapidly dividing cells even if its tumor suppressive function is compromised by other mechanisms.
• DNA Repair and Stability: Genes like PRKDC (DNA-PKcs), involved in DNA repair pathways (e.g., non-homologous end joining), also show increased expression fraction. This could reflect increased genomic instability and DNA damage associated with rapid proliferation in tumor cells, requiring more active repair mechanisms. YWHAG (14-3-3 gamma) plays roles in cell cycle control and DNA damage response, often implicated in cancer progression GeneCards: YWHAG.
• Epigenetic Modulation: HDAC2, a histone deacetylase, is also upregulated. HDACs are frequently deregulated in cancer, promoting cell proliferation and survival by altering chromatin structure and gene expression PubMed Search: HDAC2 cancer proliferation.

Overall, these findings provide strong evidence that Intestinal Epithelial cells in colon tumors are characterized by a highly active and dysregulated cell cycle machinery, driving tumor growth and expansion.

Clinical or Translational Implications

The pervasive upregulation of cell cycle genes in Intestinal Epithelial cells from colon tumors has significant clinical and translational implications:

• Biomarkers of Proliferation: These genes could serve as valuable biomarkers for assessing tumor proliferation rates, distinguishing malignant from normal tissue, and potentially for prognosis in colon cancer. Their expression levels, or the fraction of cells expressing them, could be integrated into diagnostic panels.
• Therapeutic Targets: Many of the identified genes represent established or emerging therapeutic targets in oncology. For instance, CDK4/6 inhibitors target cell cycle progression driven by Cyclin D (CCND1/3) and RB1 pathway dysregulation, which are relevant here. Inhibitors against MYC or specific HDACs are also being developed or are in clinical use. The consistent upregulation across multiple components of the cell cycle machinery in tumor-origin cells suggests that targeting cell cycle progression could be an effective strategy for colon cancer.
• Understanding Tumor Progression: The data provides insight into the fundamental biological processes driving colon tumor development at the cellular level. By understanding which specific cell cycle components are most consistently and significantly altered, researchers can better elucidate the molecular mechanisms of colon cancer progression and identify vulnerabilities.
• Monitoring Treatment Response: In the future, measuring the "expressing cell fraction" of these key cell cycle genes could potentially be used to monitor treatment response to anti-proliferative therapies, indicating whether tumor cells are reducing their proliferative activity.

20. Gene Ontology (GSA) Analysis for Intestinal Epithelial Cells

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Gene Ontology (GO) enrichment results (Gene Set Analysis, GSA_up) for Intestinal Epithelial cells, comparing three distinct cellular states:

1. Adj_normal_vs_others: Pathways upregulated in Intestinal Epithelial cells from "Adjacent Normal" tissue compared to all other Intestinal Epithelial cells (primarily those from "Tumor" tissue).
2. Diploid_vs_others: Pathways upregulated in Intestinal Epithelial cells inferred to be "Diploid" compared to those inferred as "Aneuploid."
3. Tumor_vs_others: Pathways upregulated in Intestinal Epithelial cells from "Tumor" tissue compared to all other Intestinal Epithelial cells (primarily those from "Adjacent Normal" tissue).

The results are displayed as bar plots, where the length of the bar corresponds to the statistical significance (-log(p-val) and -log(q-val)) of the enrichment.

Visual Summary

The provided bar plots highlight distinct functional differences across the analyzed conditions and ploidy states within Intestinal Epithelial cells.

• Adjacent Normal Intestinal Epithelial Cells (Adj_normal_vs_others): This comparison reveals a significant enrichment of metabolic pathways, including fatty acid degradation, amino acid metabolism (valine, leucine, isoleucine degradation), ketone body synthesis and degradation, and butanoate metabolism. Pathways like PPAR signaling, oxidative phosphorylation, and mineral absorption are also prominent, indicating a highly active metabolic state. Cell-cell adhesion terms like "tight junction" and "focal adhesion" suggest intact epithelial barrier function. There's also an enrichment of certain disease pathways (e.g., Diabetic cardiomyopathy, Non-alcoholic fatty liver disease, Parkinson disease), which may reflect broader systemic metabolic influences or shared molecular mechanisms rather than primary pathology in these normal cells.
• Diploid Intestinal Epithelial Cells (Diploid_vs_others): This plot shows a strong enrichment of pathways related to immune response and host defense. Prominent terms include "Coronavirus disease," "Toll-like receptor signaling pathway," "Epstein-Barr virus infection," "Vibrio cholerae infection," "NF-kappa B signaling pathway," and "Viral protein interaction with cytokine and cytokine receptor." Ribosome biogenesis and protein synthesis are also highly enriched, along with some metabolic pathways like "glycine, serine and threonine metabolism" and "cholesterol metabolism." This suggests that diploid cells, often representing a more stable or non-transformed state, are actively engaged in immune surveillance and maintaining basic cellular machinery.
• Tumor Intestinal Epithelial Cells (Tumor_vs_others): This comparison demonstrates the most extensive and highly significant pathway enrichment, strongly indicative of malignant transformation. Top enriched pathways include "Protein processing in endoplasmic reticulum," "Spliceosome," "RNA transport," "Ribosome," "Cell cycle," "Ubiquitin mediated proteolysis," and "Autophagy," pointing to extensive dysregulation in protein and RNA metabolism, and cellular stress responses. Direct cancer-related pathways such as "Colorectal cancer," "Pathways in cancer," "p53 signaling pathway," and "Cellular senescence" are highly enriched. Additionally, numerous infection-related pathways (e.g., "Salmonella infection," "Human papillomavirus infection," "Hepatitis B," "Coronavirus disease") and neurodegenerative disease pathways (e.g., "Amyotrophic lateral sclerosis," "Huntington disease," "Alzheimer disease," "Parkinson disease") are also upregulated, which often share common themes of protein misfolding, cellular stress, and immune evasion that are frequently hijacked by cancer cells. Changes in cell adhesion are indicated by "Adherens junction."

Biological Interpretation

These GSA results provide a comprehensive biological understanding of Intestinal Epithelial cells in the context of colorectal cancer, considering both tissue origin and ploidy status.

1. Metabolic Reprogramming in Normal vs. Tumor Epithelium: Adjacent normal Intestinal Epithelial cells exhibit high metabolic activity, particularly in lipid and amino acid catabolism, essential for maintaining gut homeostasis and energy supply. The PPAR signaling pathway, crucial for lipid metabolism and anti-inflammatory responses, is highly active [1]. In contrast, tumor cells display a shift towards pathways related to increased protein synthesis and processing (ER protein processing, ribosome, spliceosome) and RNA metabolism (RNA transport, RNA degradation), indicative of high proliferative demand and stress within the malignant cells. This metabolic shift is a hallmark of cancer, where cells prioritize anabolism to support rapid growth [2].
2. Immune Surveillance and Ploidy: Diploid Intestinal Epithelial cells show a robust upregulation of immune-related pathways, including Toll-like receptor signaling and NF-kappa B signaling, which are critical for recognizing pathogens and initiating inflammatory responses [3]. The enrichment of pathways related to various infections (viral, bacterial) suggests that diploid cells, potentially representing a healthier or more immune-competent subpopulation, are actively involved in defending against pathogens, a constant challenge in the gut environment. This contrasts with aneuploid cells (implied by 'others'), which might have compromised immune functions or altered cellular stress responses.
3. Hallmarks of Colorectal Cancer: The enrichment in tumor Intestinal Epithelial cells directly reflects established hallmarks of cancer. The activation of "Cell cycle" pathways underscores uncontrolled proliferation. "Protein processing in endoplasmic reticulum" and "Ubiquitin mediated proteolysis" highlight significant cellular stress and increased protein turnover, often associated with rapid growth and altered protein quality control in cancer. The appearance of "Colorectal cancer" and "Pathways in cancer" terms explicitly confirms the cancerous state. The concurrent upregulation of "Autophagy" and "Cellular senescence" pathways suggests complex adaptive and maladaptive stress responses within the tumor cells, potentially promoting survival or contributing to resistance [4]. Changes in "Adherens junction" integrity are crucial for epithelial-mesenchymal transition (EMT) and metastasis [5].

Clinical or Translational Implications

• Therapeutic Targets in Colorectal Cancer: The identified highly enriched pathways in tumor Intestinal Epithelial cells, such as those involved in protein processing (ER protein processing, Spliceosome, Ribosome), RNA metabolism, and cell cycle regulation, represent promising targets for novel therapeutic interventions in colorectal cancer. Inhibitors of these pathways could selectively target rapidly dividing and stressed cancer cells.
• Ploidy as a Prognostic Factor/Biomarker: The distinct functional profile of diploid vs. aneuploid Intestinal Epithelial cells suggests that ploidy status is not merely a genetic aberration but reflects profound differences in cellular biology, particularly regarding immune competence and basic cellular maintenance. This reinforces the potential of ploidy as a prognostic biomarker or for stratifying patients for therapies that might modulate immune responses or cellular stress.
• Understanding Tumor-Microenvironment Interactions: The consistent appearance of infection and inflammation-related pathways across different comparisons, particularly in diploid cells and tumor cells, underscores the complex interplay between the gut microbiome, inflammation, and colorectal cancer development. Modulating the microbiome or targeting inflammatory pathways could be complementary therapeutic strategies.
• Drug Repurposing Opportunities: The overlap of certain cancer pathways with neurodegenerative diseases or metabolic disorders (e.g., Parkinson's, ALS, NAFLD) suggests shared molecular mechanisms that could open avenues for drug repurposing, where existing drugs for one condition might be effective against colorectal cancer by targeting common upstream processes.

---

References:

[1] PPAR signaling pathway. *KEGG Pathway Database*. https://www.genome.jp/pathway/hsa03320

[2] Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. *Cell*, 144(5), 646–674. https://pubmed.ncbi.nlm.nih.gov/21376720/

[3] Toll-like receptor signaling pathway. *KEGG Pathway Database*. https://www.genome.jp/pathway/hsa04620

[4] Levy, J. M., Towers, C. G., & Thorburn, A. (2017). Targeting autophagy in cancer. *Nature Reviews Cancer*, 17(9), 528–542. https://pubmed.ncbi.nlm.nih.gov/28775439/

[5] Adherens junction. *KEGG Pathway Database*. https://www.genome.jp/pathway/hsa04520

21. Gene Set Enrichment Analysis Reveals Condition- and Cell Type-Specific Pathway Alterations in Colon Tissue

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Gene Set Enrichment Analysis (GSEA) results for key cell types found in colon tissue, comparing Tumor and Adjacent Normal (Adj_normal) conditions. For Intestinal Epithelial Cells (IECs), the analysis further distinguishes between diploid and aneuploid cell populations. The dot plot visualizes the Normalized Enrichment Score (NES) and statistical significance (-log(p-val)) for 120 selected gene sets, providing insights into the biological pathways differentially activated or suppressed in various cell types under different disease and ploidy states.

Visual Summary

The dot plot effectively summarizes the GSEA results, with each dot representing a gene set (y-axis) enriched in a specific cell type and comparison context (x-axis).

• X-axis: Displays distinct cell type comparisons, such as "B cell: Adj_normal_vs_others" (referring to B cells in Adj_normal vs. B cells in Tumor) or "Intestinal Epithelial cell: Diploid_Tumor_vs_others" (referring to diploid IECs in Tumor vs. diploid IECs in Adj_normal, or other relevant comparisons within IECs).
• Y-axis: Lists various biological pathways and processes, including metabolic pathways, immune signaling, cell cycle regulation, and cancer-associated pathways.
• Dot Color (NES): A red-to-blue colormap ('RdBu_r') is used. Red dots indicate a positive NES, meaning the gene set is significantly enriched (upregulated) in the "test" condition (e.g., Tumor cells in "Tumor_vs_others" or Adj_normal cells in "Adj_normal_vs_others"). Blue dots indicate a negative NES, meaning the gene set is significantly enriched (upregulated) in the "reference" or "others" group (e.g., Adj_normal cells when comparing "Tumor_vs_others", or downregulated in the test group).
• Dot Size (-log(p-val)): The size of each dot is proportional to the statistical significance, with larger dots representing more significant enrichment (smaller p-values).

Overall, the plot reveals widespread and distinct pathway perturbations across different cell types and conditions, with particularly strong and numerous signals observed in Intestinal Epithelial Cells, immune cells (Macrophages, T cells, B cells, Plasma cells, ILCs), and stromal cells (Fibroblasts, Endothelial cells). The inclusion of ploidy-specific comparisons for IECs highlights specific metabolic and proliferative differences.

Biological Interpretation

1. Intestinal Epithelial Cells (IECs) Undergoing Malignant Transformation:

• Metabolic Reprogramming (Warburg Effect): Tumor IECs (both diploid and aneuploid) show strong upregulation of pathways like Glycolysis / Gluconeogenesis, Cholesterol metabolism in cancer, Purine metabolism, and Pyrimidine metabolism. Conversely, Oxidative phosphorylation is significantly downregulated in tumor IECs while being upregulated in adjacent normal IECs. This pattern is characteristic of the Warburg effect, where cancer cells favor glycolysis even in the presence of oxygen to support rapid proliferation and biomass synthesis PubMed Search: Warburg effect cancer metabolism.
• Oncogenic Signaling: The Wnt signaling pathway is notably upregulated in tumor IECs, a well-established driver of colorectal cancer development and progression PubMed Search: Wnt signaling colorectal cancer. HIF-1 signaling pathway is also enriched, indicating adaptation to hypoxia within the tumor microenvironment.
• Cell Cycle and DNA Repair in Aneuploidy: Aneuploid tumor IECs exhibit a marked upregulation of pathways related to DNA replication, Cell cycle, Homologous recombination, and Non-homologous end-joining. This suggests intense proliferative activity and robust DNA repair mechanisms in these genetically unstable cells. Consistent with this, the p53 signaling pathway is downregulated in aneuploid tumor IECs, indicating a loss of crucial tumor suppressor function PubMed Search: aneuploidy p53 cancer.
• Other Tumor-associated Processes: Pathways like Protein processing in endoplasmic reticulum, Autophagy, Cellular senescence, and MicroRNAs in cancer are also enriched in tumor IECs, reflecting the complex cellular stress responses and regulatory shifts in transformed cells.

2. Tumor Microenvironment and Immune Cell Modulation:

• Macrophages: In the tumor microenvironment, macrophages show upregulation of HIF-1 signaling pathway, TNF signaling pathway, and Wnt signaling pathway, suggesting their polarization towards pro-tumorigenic phenotypes (e.g., M2-like) or involvement in chronic inflammation under hypoxic conditions. In contrast, adjacent normal macrophages are enriched for fundamental immune functions like Phagosome and Lysosome pathways.
• T cells (CD4+ and CD8+): Both CD4+ and CD8+ T cells in the tumor exhibit upregulation of pathways such as T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Cytokine-cytokine receptor interaction, and TNF signaling pathway. This indicates T cell activation and differentiation within the tumor, which can represent anti-tumor immunity, pro-tumorigenic responses (e.g., specific Th subsets), or T cell exhaustion depending on the specific context. The enrichment of the Inflammatory bowel disease pathway in T cells from tumor further highlights the inflammatory nature of the colon tumor microenvironment.
• B cells and Plasma cells: In the tumor, Plasma cells show enrichment for B cell receptor signaling pathway and Antigen processing and presentation, along with immune-related disorders like Rheumatoid arthritis and Autoimmune thyroid disease, suggesting activated antibody-producing cells contributing to tumor immunity or inflammation. Similarly, B cells in the tumor show activation of B cell receptor signaling pathway, TNF signaling pathway, and NF-kappa B signaling pathway, consistent with their involvement in immune responses.
• ILCs: Innate Lymphoid Cells (ILCs) in the tumor also show enrichment for Th1 and Th2 cell differentiation and Cytokine-cytokine receptor interaction, indicating their role in shaping the immune response within the tumor.

3. Stromal Contributions to Tumor Progression:

• Fibroblasts: Tumor-associated fibroblasts (CAFs) show strong upregulation of pathways like HIF-1 signaling pathway, Wnt signaling pathway, Cytokine-cytokine receptor interaction, ECM-receptor interaction, and Focal adhesion. These findings align with the established role of CAFs in extracellular matrix remodeling, promoting angiogenesis, and secreting growth factors that support tumor growth and invasion PubMed Search: CAFs tumor microenvironment.
• Endothelial Cells: Endothelial cells in the tumor are enriched for HIF-1 signaling pathway and Wnt signaling pathway, reflecting their involvement in angiogenesis and vascular remodeling, which is crucial for tumor blood supply and metastasis.

Clinical or Translational Implications

1. Therapeutic Targeting of Wnt and HIF-1 Pathways: The consistent upregulation of Wnt signaling pathway in tumor IECs, fibroblasts, macrophages, and T cells, and HIF-1 signaling pathway across multiple cell types (IECs, macrophages, fibroblasts, endothelial cells), suggests these are central drivers of colorectal cancer pathobiology. Targeting these pathways could offer broad therapeutic benefits, impacting not only cancer cells but also key components of the tumor microenvironment.
2. Metabolic Reprogramming as a Therapeutic Vulnerability: The pronounced metabolic shift towards glycolysis and increased anabolism in tumor IECs (Warburg effect) highlights the potential for anti-cancer therapies that target specific metabolic enzymes or pathways.
3. Immuno-oncology Strategies: The widespread activation and differentiation of various immune cells (T cells, B cells, Plasma cells, Macrophages, ILCs) and the enrichment of inflammatory pathways underscore the dynamic immune landscape in colorectal cancer. Understanding the precise pro- or anti-tumorigenic roles of these activated immune cell subsets is crucial for developing effective immunotherapies, such as checkpoint inhibitors or adoptive cell therapies. The Inflammatory bowel disease pathway enrichment in T cells suggests a chronic inflammatory component that could be targeted to modulate immune responses.
4. Aneuploidy-Specific Therapeutic Approaches: The distinct activation of DNA replication, cell cycle, and DNA repair pathways, coupled with p53 downregulation in aneuploid tumor IECs, suggests that these cells might be particularly susceptible to therapies that disrupt cell cycle progression or DNA integrity. Conversely, they might exhibit resistance to conventional treatments due to enhanced repair mechanisms. This highlights the importance of ploidy status in guiding precision medicine strategies.
5. Targeting Stromal-Tumor Interactions: The activation of CAFs and endothelial cells and their involvement in ECM remodeling and angiogenesis (indicated by HIF-1, Wnt, and ECM-related pathways) emphasizes the importance of targeting the tumor microenvironment. Anti-angiogenic therapies or agents that modulate CAF function could impede tumor growth and metastasis.

22. Discussion

The comprehensive single-cell analysis of human colon tissue reveals a profoundly altered cellular and molecular landscape in colon cancer compared to adjacent normal tissue. A central finding is the clear identification of malignant Intestinal Epithelial cells, the tumor origin cell type, which are largely defined by pervasive aneuploidy and extensive genomic instability, as evidenced by widespread copy number variations (CNVs). Notably, amplification of the *EGFR*-containing region (7p14.1:7q11.23) is a recurrent event in these tumor cells, underscoring a key oncogenic driver. The distinct clustering of aneuploid, epithelial, and tumor-derived cells in CNV-based UMAPs further validates their malignant identity and highlights intratumoral heterogeneity, with some tumor samples containing significant diploid epithelial populations, possibly representing less transformed or reactive cells.

Beyond the malignant epithelium, the tumor microenvironment (TME) undergoes substantial reprogramming. Immune cell populations exhibit significant shifts, notably a pronounced increase in immunosuppressive T regulatory (Treg) cells and Th17 cells, alongside a depletion of anti-tumorigenic ILC1 and ILC2 populations. This suggests an immune landscape skewed towards immune evasion and chronic inflammation. Macrophages within the TME also display altered polarization, with a significant increase in pro-tumorigenic M2B macrophages and a decrease in M2A macrophages, indicating their active contribution to an immunosuppressive and angiogenesis-promoting environment. Cancer-associated fibroblasts (CAFs), identified by markers such as FAP and PDGFRB, are highly activated in tumor tissue, driving extensive extracellular matrix remodeling through upregulated collagen-integrin interactions.

Cell-cell interaction analysis further elucidates the complex communication network within the TME. A shift from epithelial-stromal homeostatic interactions in normal tissue to dominant interactions between aneuploid epithelial cells, macrophages, and activated fibroblasts is observed in tumors. Prominently, EREG-EGFR interactions mediate communication between tumor cells and immune cells, promoting growth. Pro-inflammatory and pro-angiogenic signals are amplified, including IL6-IL6R, VEGFA-VEGFR1/VEGFR2, and Ephrin-Eph receptor signaling, particularly involving macrophages and tumor epithelial cells. Crucial immune checkpoint and co-stimulatory axes, such as CD86-CD28, are highly active, suggesting ongoing but potentially exhausted immune responses. Upregulation of Prostaglandin E2, CXCL12-CXCR4, and TGFB1-TGFbeta_receptor1 interactions within the TME further points to key pathways driving immunosuppression and stromal remodeling.

Gene expression and pathway analyses underscore these cellular and microenvironmental changes. Tumor Intestinal Epithelial cells exhibit pervasive and highly significant upregulation of cell cycle genes (e.g., CCND1, MYC), confirming uncontrolled proliferation. GSEA results highlight metabolic reprogramming in tumor IECs towards glycolysis (Warburg effect) and away from oxidative phosphorylation, along with activated Wnt and HIF-1 signaling pathways. Aneuploid tumor IECs specifically show activation of DNA replication and repair pathways alongside downregulation of p53 signaling, indicating both genomic instability and compromised tumor suppression. Across the TME, Wnt and HIF-1 signaling are consistently upregulated in various cell types (fibroblasts, macrophages, endothelial cells), suggesting their central role in shaping the tumor. These findings collectively paint a picture of highly coordinated oncogenic processes impacting tumor cells and their supportive microenvironment in colon cancer.

Hypotheses:

1. Aneuploid Intestinal Epithelial cells in colon tumors, characterized by recurrent *EGFR* amplification and pervasive cell cycle dysregulation, are the primary drivers of tumor growth and metastatic potential, distinct from diploid epithelial cells.
2. The profound immune dysregulation in the colon TME, marked by increased Treg cells and M2B macrophages and decreased ILC1 cells, directly contributes to immune evasion by suppressing anti-tumor effector functions and promoting chronic inflammation.
3. Reprogrammed cancer-associated fibroblasts (CAFs) actively remodel the extracellular matrix and engage in pro-tumorigenic cell-cell interactions (e.g., via CXCL12-CXCR4, TGFB1-TGFbeta_receptor1, FAP) that recruit immunosuppressive cells and foster tumor cell invasion.
4. The shift in EGFR ligand usage from AREG/HBEGF in normal epithelium to EREG in tumor cells, coupled with its interaction with immune cells, represents a mechanism by which tumor cells actively manipulate the microenvironment for their survival and proliferation.
5. Metabolic reprogramming, including heightened glycolysis (Warburg effect) and cholesterol/purine/pyrimidine metabolism, is a fundamental vulnerability of colon cancer cells, particularly aneuploid Intestinal Epithelial cells, supporting their rapid proliferation and biomass accumulation.

Potential therapeutic targets:

1. EGFR (Epidermal Growth Factor Receptor): Recurrent amplification of the *EGFR*-containing region (7p14.1:7q11.23) in tumor Intestinal Epithelial cells, along with upregulated expression of its ligand EREG and activation of EREG-EGFR interactions between tumor and immune cells. EGFR signaling is a known driver of proliferation and survival in colorectal cancer. Evidence: CNV analysis (Section 4), condition-specific surfaceome markers for Intestinal Epithelial cells (MET, EREG are co-upregulated) (Section 15), and immune checkpoint/cell cycle focused CCI (EREG-EGFR interactions between Aneuploid Intestinal Epi and T CD8+/Mac) (Section 13). Validation: Test existing EGFR inhibitors (e.g., cetuximab, panitumumab) or novel EREG-specific blocking agents in preclinical models or in patient cohorts selected for EGFR amplification or high EREG expression; monitor tumor cell proliferation and immune modulation.
2. TACSTD2 (TROP2): Highly specific and significantly upregulated surface marker on tumor Intestinal Epithelial cells, particularly in aneuploid populations. TROP2 is a well-established target for antibody-drug conjugates (ADCs) in epithelial cancers. Evidence: Condition-specific surfaceome markers for Intestinal Epithelial cells show strong, pervasive expression of TACSTD2 in tumor samples (Section 15). Validation: Evaluate the efficacy of TROP2-targeting ADCs (e.g., Sacituzumab govitecan) in colon cancer models or in clinical trials, especially in patients with high TROP2 expression in their tumors.
3. FAP (Fibroblast Activation Protein): FAP is a canonical and highly specific surface marker for cancer-associated fibroblasts (CAFs) in colon tumors. CAFs drive ECM remodeling, immune suppression, and tumor growth, representing a critical component of the pro-tumorigenic microenvironment. Evidence: Condition-specific surfaceome markers for Fibroblasts show strong upregulation of FAP in tumor samples (Section 17). Increased COL-integrin interactions in tumor suggest active CAF remodeling (Section 14). Validation: Develop or test FAP-targeting agents (e.g., FAP-specific ADCs, FAP-CAR-T cells, or FAP inhibitors) to deplete or reprogram CAFs in colon cancer models, assessing impact on tumor growth, metastasis, and immune infiltration/function.
4. Treg cells / CTLA4: Treg cells are significantly enriched in the tumor microenvironment and are potent immunosuppressors, contributing to immune evasion. CTLA4 is a key immune checkpoint receptor expressed on Tregs and activated T cells, mediating their suppressive function. Evidence: T cell subset analysis shows significantly higher Treg proportion in Tumor (Section 7, 8). Condition-specific surfaceome markers for T cell CD4+ show upregulation of CTLA4 in tumor (Section 18). Validation: Test CTLA4 blocking antibodies (e.g., ipilimumab) alone or in combination with other immunotherapies in colon cancer patients, evaluating reduction in Treg activity and enhancement of anti-tumor effector T cell responses.
5. M2B Macrophages / MMP14 / TREM2: M2B macrophages are significantly increased in the tumor microenvironment and are implicated in immune suppression, angiogenesis, and tumor progression. MMP14 and TREM2 are highly expressed surface markers on tumor macrophages, mediating ECM remodeling and TAM survival/immunosuppression, respectively. Evidence: Macrophage subset analysis shows significantly higher M2B proportion in Tumor (Section 9, 10). Condition-specific surfaceome markers for Macrophages show high MMP14 and TREM2 expression in tumor macrophages (Section 16). Validation: Explore strategies to reprogram M2B macrophages or specifically target MMP14 or TREM2 activity (e.g., using small molecule inhibitors or blocking antibodies) in preclinical colon cancer models, assessing impact on tumor growth, angiogenesis, and immune context.

Follow-up validation ideas:

1. Targeted qPCR/Immunostaining/Flow Cytometry: Validate the differential expression of key surface markers (e.g., TROP2, MET, CEACAM6 on tumor IECs; FAP, PDGFRB, B7-H3 on CAFs; MMP14, TREM2 on TAMs; TIGIT, CTLA4, OX40 on T cells) in larger patient cohorts using bulk tissue, flow cytometry of dissociated cells, or spatial transcriptomics/immunostaining to confirm their cell-type and condition specificity and explore prognostic value.
2. In vitro Perturbation Assays: Use patient-derived organoids or cell lines to functionally investigate the impact of perturbing key pathways (e.g., EGFR signaling using EREG, Wnt signaling, HIF-1 signaling) on cell proliferation, survival, and differentiation in aneuploid Intestinal Epithelial cells, especially in 3D culture models that mimic tissue architecture.
3. In vivo Efficacy Studies: Test the therapeutic potential of targeting identified pathways or surface markers (e.g., TROP2 ADCs, FAP inhibitors, B7-H3 blocking antibodies, or agents modulating M2B macrophage polarization or Treg function) in patient-derived xenograft (PDX) models or syngeneic mouse models of colon cancer.
4. Functional Immune Assays: Conduct co-culture experiments with tumor cells, CAFs, and specific immune cell subsets from colon cancer patients to validate critical cell-cell interactions (e.g., CD86-CD28, CXCL12-CXCR4, TGFB1-TGFbeta_receptor1, IL6-IL6R, Ephrin-Eph) and their effects on immune cell activation, differentiation, and anti-tumor effector functions.
5. CNV-FISH/ArrayCGH Validation: Perform Fluorescence In Situ Hybridization (FISH) or array Comparative Genomic Hybridization (aCGH) on macro-dissected tumor regions or single cells to confirm recurrent genomic amplifications (e.g., *EGFR*) and validate aneuploidy status in a larger cohort.
6. Metabolic Flux Analysis: Use Seahorse Analyzer or stable isotope tracing in aneuploid Intestinal Epithelial cell lines or organoids to quantify metabolic shifts (e.g., glycolysis, oxidative phosphorylation rates) and confirm the Warburg effect and other metabolic vulnerabilities.

Limitations:

This single-cell RNA sequencing analysis provides a high-resolution view of cellular and molecular changes in colon cancer. However, it is based on a snapshot of gene expression and does not fully capture dynamic processes, protein-level modifications, or the spatial organization of cells, which are crucial aspects of tumor biology. While computational methods infer copy number variations and cell-cell interactions, these require orthogonal experimental validation. The observed associations between molecular profiles and disease state or ploidy status are correlative, and functional causality needs to be established through further experimental studies. The patient cohort size, while providing robust trends, might not capture the full spectrum of inter-patient heterogeneity in colorectal cancer.

23. Query List

1. Show and save UMAPs for condition, sample, major cell type, minor cell type, ploidy_dec, and celltype_subset in two columns.
2. Show major cell type scores on UMAP and save the result.
3. Show and save a marker expression dot plot for celltype_subset. SET target_cell = None and var_group_rotation = 45. Leave all other arguments at their default values.
4. Select Intestinal Epithelial cells, show a CNV heatmap grouped by sample together with a summary of regions with significantly amplified copy numbers, and save the results.
5. Show and save UMAPs of CNV patterns colored by major cell type, minor cell type, ploidy results, condition, and sample in two columns.
6. Show and save a population bar plot of minor cell types.
7. Show and save a population bar plot of T cell subsets.
8. Show and save box plots of T cell subset populations with statistically significant differences between conditions, if any. Choose ncols based on the total number of panels.
9. Show and save a population bar plot of macrophage subsets.
10. Show and save box plots of macrophage subset populations with statistically significant differences between conditions, if any. Choose ncols based on the total number of panels.
11. Select Intestinal Epithelial cells, show their ploidy populations as a bar plot, and save the result.
12. Show and save cell-cell interaction patterns involving Intestinal Epithelial cells, Fibroblast, Macrophage, T cell CD4+, and T cell CD8+. Select at most 80 cell-cell interactions per group.
13. Select only genes associated with immune checkpoint and cell cycle pathways, show cell-cell interactions for these genes, and save the result.
14. Find cell-cell interactions involving major immune and stromal cells that differ significantly between conditions, show them as a dot plot, and save the result. Set max_n_items_per_group to 60.
15. Extract condition-specific markers for Intestinal Epithelial cells, show their expression as a dot plot, and save the result. Use only surfaceome markers, with at most 50 markers per condition.
16. Extract condition-specific markers for Macrophage to show the markers expression as a dot plot, and save the result. Use only surfaceome markers, with at most 30 markers per condition.
17. Extract condition-specific markers for Fibroblast to show the markers expression as a dot plot, and save the result. Use only surfaceome markers, with at most 30 markers per condition.
18. Extract condition-specific markers for T cell CD4+ to show the markers expression as a dot plot, and save the result. Use only surfaceome markers, with at most 30 markers per condition.
19. Among cell cycle pathway genes, select those with statistically significant expression differences between conditions in Intestinal Epithelial cells, show box plots, and save the result. Set max_n_items_to_plot to 24 and choose ncols based on the total number of panels for an overall width-to-height ratio of approximately 2:3.
20. Show and save Gene Ontology (GSA) analysis results for Intestinal Epithelial cells as a bar plot.
21. Show Gene Set Enrichment Analysis results as a dot plot, and save it. Set the color map to RdBu_r and n_pws_to_show to 120.